University of Kentucky

UKnowledge
University of Kentucky Doctoral Dissertations

Graduate School

2011

GENOTOXIN-INDUCED ACETYLATION OF THE WERNER
SYNDROME PROTEIN (WRN) AND EFFECT ON ITS DNA
METABOLIC FUNCTION
Enerlyn Meliza Lozada Santiago
University of Kentucky, enerlyn@gmail.com

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Lozada Santiago, Enerlyn Meliza, "GENOTOXIN-INDUCED ACETYLATION OF THE WERNER SYNDROME
PROTEIN (WRN) AND EFFECT ON ITS DNA METABOLIC FUNCTION" (2011). University of Kentucky
Doctoral Dissertations. 817.
https://uknowledge.uky.edu/gradschool_diss/817

This Dissertation is brought to you for free and open access by the Graduate School at UKnowledge. It has been
accepted for inclusion in University of Kentucky Doctoral Dissertations by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

ABSTRACT OF DISSERTATION

Enerlyn Meliza Lozada Santiago

The Graduate School
University of Kentucky
2011

GENOTOXIN-INDUCED ACETYLATION OF THE WERNER SYNDROME
PROTEIN (WRN) AND EFFECT ON ITS DNA METABOLIC FUNCTION

ABSTRACT OF DISSERTATION

A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in the College of Medicine at the University of Kentucky

By
Enerlyn Meliza Lozada Santiago
Lexington, Kentucky
Director: Dr.David Orren, Professor of Toxicology
Lexington, Kentucky
2011
Copyright © Enerlyn Meliza Lozada Santiago 2011

ABSTRACT OF DISSERTATION

GENOTOXIN-INDUCED ACETYLATION OF THE WERNER SYNDROME
PROTEIN (WRN) AND EFFECT ON ITS DNA METABOLIC FUNCTION
Loss of function of the WRN protein causes the genetic disorder Werner Syndrome that
is characterized by increased cancer and premature aging. WRN belongs to the RecQ
helicase family that plays key roles in preventing genome instability. In response to
treatment with genotoxins, WRN is subject to post-translational modification. The
relationship of post-translational modification of WRN with its function in DNA
metabolism is unknown. There is accumulating evidence suggesting that WRN
contributes to the maintenance of genomic integrity through its involvement in DNA
replication. Consistent with this notion, WS cells are sensitive to DNA replication
inhibitors and DNA damaging agents that tend to block replication fork progression. The
cells exhibit an extended S phase, as well as defects in normal bi-directional progression
of replication forks diverging from the majority of replication origins. To elucidate the
relationship between post-translational modifications of WRN with its function in DNA
metabolism, here the acetylation of WRN was studied. In our studies, we provide
evidence that WRN acetylation is a dynamic process that strongly correlates to blockage
of replication by persistent DNA damage. We also determined the effect of WRN
acetylation on its specificity and enzymatic functions. In addition, our studies reveal how
agents that block replication regulate the nature of WRN interactions with RPA, a factor
known to bind to single-stranded DNA generated at blocked replication forks. Our results
demonstrated that WRN and RPA form a stable direct association under normal
physiological conditions and treatments that block replication fork progression increase
their association, further supporting the idea that WRN is involved in DNA replication
through its action at blocked or stalled replication forks. Thus, these studies point to both
1) an important role for acetylation of WRN and 2) its interaction with RPA in the
putative function of WRN in response to blocked replication. Overall, our results impact
knowledge regarding the relationship between DNA damage, genome instability and the
development and progression of aging and cancer.
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CHAPTER I

INTRODUCTION

WERNER SYNDROME
Werner Syndrome (WS) is a rare autosomal recessive genetic disease caused by a
deficiency of a single gene product known as WRN. This syndrome was first identified
by Otto Werner, a German scientist who described the syndrome in his doctoral thesis in
1904. WS is characterized by increased cancer and early onset or increased frequency of
specific age-related phenotypes, including graying and loss of hair, skin ulceration,
atherosclerosis, osteoporosis, cataracts, hypertension, and diabetes mellitus type II [Goto
et al., 1997; Chen et al., 2002; Orren 2006]. The syndrome has specific symptoms not
found in normal aging, including short stature, hyperkeratosis and soft tissue
calcification. WS patients usually develop normally until they reach the second decade of
life. In fact, most WS patients are not diagnosed until their 20’s or even 30’s. The median
age of patients who die from WS is 54. Primarily they die from cancer or cardiovascular
disease [Huang et al., 2006]. Because of this large overlap with normal aging, the
relatively normal early development, and the mildness of aging symptoms, it is believed
that WS is an excellent model system for the study of human aging [Martin et al., 1978].

ROLE OF WRN IN GENOME MAINTENANCE

Cells from WS patients show several distinct abnormalities when compared with
normal cells, including elevated frequency of spontaneous chromosomal aberrations
characterized by deletions, insertions, and translocations as well as an increased rate of
telomere shortening [Gebhart et al., 1988; Honma et al., 2002]. In an effort to determine
the role of WRN in DNA metabolism, WRN-deficient cells have been subjected to many
DNA damaging regimens. They are hypersensitive to DNA damaging agents such as 4nitroquinolone-1-oxide (4NQO), interstrand crosslinking agents including mitomycin C
(MMC) and cisplatin, and topoisomerase inhibitors such as camptothecin [Gebhart et al.,
1

1988; Ogburn et al., 1997; Poot et al., 1999]. In addition, they are hypersensitive to
agents that tend to block progression of replication forks, including hydroxyurea (HU)
[Pichierri et al., 2001]. Together, this evidence suggests that WRN functions in cellular
responses to maintain genome stability, such as DNA repair, replication and/or
recombination pathways. However, the sensitivity of WS cells to damaging agents does
not appear to reflect a direct role in an established DNA repair pathway. Instead,
sensitivity to certain DNA damaging agents and HU suggest that WRN plays a role in
responding to replication blockage by lesions or other obstructions.

Additional evidence supports the role of WRN in DNA replication. WRN expression
is upregulated during S phase in highly proliferative transformed cell lines [Kawabe et
al., 2000b]. WS cells have dramatically reduced replicative capacity leading to very early
cellular senescence; they grow slowly and have been reported to have a longer S phase as
well as possibly replication initiation and elongation abnormalities [Martin et al., 1970;
Takeuchi et al., 1982b; Salk et al., 1985; Poot et al., 1992; Yan et al., 1998]. WRNdeficient cells are defective in normal bi-directional progression of replication forks
diverging from the majority of replication origins [Rodriguez-Lopez et al., 2002]. This
suggests a high frequency of replication fork stalling and is consistent with the notion that
WRN may play an important but non-essential role in replication [Takeuchi et al., 1982a;
Hanaoka et al., 1985]. Thus, it has been suggested that WRN is involved either in
preventing the collapse of stalled replication forks or in resolving intermediates present at
blocked forks. Consistent with this idea, recent studies have shown that:

1) upon

replication arrest, WRN is redistributed to distinct nuclear foci (where it co-localizes with
RPA) and is phosphorylated and acetylated [Constantinou et al., 2000; Sakamoto et al.,
2001; Blander et al., 2002], and 2) WRN can coordinate its unwinding and pairing
activities to regress a model replication fork substrate [Machwe et al., 2006 and 2007].
From these observations (summarized in Table 1.1), it seems likely that WRN plays a
role in a DNA metabolic pathway that allows the cell to properly deal with blockage of
replication forks. Thus, the nature of genomic instability, increased cancer and premature
aging observed in WS may be the result of improper resolution of blocked replication and
illegitimate recombination caused by loss of WRN function.
2

Table 1.1 Evidence indicating a role of WRN in the maintenance of genomic integrity
through its involvement in DNA replication

Findings

References

WS cells exhibit a reduced replicative life span.

Martin et al., 1970; Salk et al., 1985

WS cells exhibit an extended S phase.

Takeuchi et al., 1982b; Poot et al., 1992

WS cells are hypersensitive to agents that tend to
block progression of replication forks.

WRN moves to nuclear foci that correspond to sites
of ongoing replication following HU and DNA
damaging treatments.
WRN expression is upregulated during S phase in
highly proliferative transformed cell lines.

Gebhart et al., 1988; Ogburn et al., 1997; Pichierri et al.,
2001; Poot et al., 1999, 2001

Karmakar et al., 2005; Sakamoto et al., 2001;
Constantinou et al, 2000

Kawabe et al., 2000b

WS cells are defective in normal bi-directional
progression of replication forks diverging from the
majority of replication origins

Rodriguez-Lopez et al., 2002

WRN regress model replication forks in vitro.

Machwe et al., 2006 and 2007

Functional and physical interaction with RPA,
FEN-1, PCNA, Topoisomerase I, and DNA
Polymerase δ

Shen et al., 1998a, 2003; Brosh et al., 1999; Doherty et
al., 2005; Sommers et al., 2005 ; Brosh et al., 2001,
2002; Sharma et al., 2004 and 2005 ; Lebel et al., 1999;
Rodriguez-Lopez et al., 2003 ; Lebel et al., 1999, Lane
et al.,2003 ; Kamath-Loeb et al., 2000, 2001; Szekely et
al., 2000
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It is well known that WRN associates or interacts directly with factors involved in
DNA replication (references in Table 1.1). For example, WRN interacts with proteins
required for lagging strand synthesis such as PCNA and FEN-1. The interaction with
PCNA is remarkable since PCNA has key roles in important processes, besides DNA
replication, such as DNA repair and recombination. WRN also interacts physically and
functionally with RPA that protects single-stranded DNA and binds to gaps at blocked
replication forks. What is more, Topo I, a protein that facilitates DNA replication by
relaxing the tension generated by winding/unwinding of DNA, interacts with WRN. This
interaction is not only physical but also functional; since WRN stimulates the ability of
Topo I to relax negatively supercoiled DNA and Topo I inhibit the ATPase activity of
WRN. However, the direct link of WRN involvement in DNA replication is its
interaction with DNA polymerase δ, a major replicative DNA polymerase. Taken
together, these observations suggest that WRN is involved in maintaining functional
DNA replication forks and absence of these interactions in WS cells might contribute to
the inability of those cells to properly respond to blockage of replication.

POST-TRANSLATIONAL MODIFICATIONS OF WRN
WRN is subject to post-translational modifications that modulate the localization and
activities of WRN upon DNA damage (Figure 1.1 summarizes the results of the latest
studies in WRN modification). Among the most common post-translational modifications
are phosphorylation, sumoylation and acetylation, all of which have been reported for
WRN.
The first reported post-translational modification on WRN was sumoylation when
endogenous and ectopically expressed WRN was shown to be modified by ubiquitin-like
SUMO-1 molecules within cells. Conjugation of SUMO to WRN has been shown to be
promoted by the nucleolar tumor suppressor p14 and the SUMO-conjugating enzyme
Ubc9 [Kawabe et al., 2000a; Woods et al., 2004]. This modification correlates with WRN
redistribution within the nucleus, suggesting that sumoylation might affect the
availability or localization of WRN.
4

Figure 1.1 Functional consequences of WRN post-translational modifications
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In addition, it has been reported that WRN is phosphorylated at multiple ser/thr
residues after DNA damaging treatments (including MMC and bleomycin) and other
agents that block DNA replication (such as HU) [Pichierri et al., 2003; Karmakar et al.,
2002 and 2005; Yannone et al., 2001; Ammazzalorso et al., 2010]. DNA-dependent
protein kinase (DNA-PK) was reported to be involved in WRN phosphorylation in vitro
and is required for WRN phosphorylation in vivo [Yannone et al., 2001; Karmakar et al.,
2002]. Interestingly, phosphorylation of WRN with DNA-PK inhibits its helicase and
exonuclease activities, suggesting that WRN modifications may be a way of regulating
WRN catalytic activities. The proteins ATR and ATM, members of the phosphoinositide
3-kinases family (PI3-Ks), as DNA-PK, phosphorylate WRN as well. ATR/ATMdependent WRN phosphorylation affects WRN translocation and co-localization with its
protein partners, including RPA, in nuclear foci after DNA damage [Pichierri et al., 2003;
Ammazzalorso et al., 2010]. Additionally, it was found that the nuclear tyrosine kinase cAbl regulates WRN phosphorylation. c-Abl phosphorylates WRN at tyrosine residues
correlating with the translocation of WRN from nucleoli to discrete nuclear foci upon
DNA damage [Cheng et al., 2003].
In addition to being sumoylated and phosphorylated, WRN is also acetylated in vivo
[Blander et al., 2002]. WRN acetylation is promoted by the acetyltransferase p300.
Interestingly, deacetylated WRN is localized in the nucleolus and acetylation of WRN
correlates with its recruitment to the nucleoplasm. Furthermore, Karmakar and colleagues
reported that DNA damaging agents, including MMC, promote WRN acetylation
[Karmakar et al., 2005]. Taken together, it is likely that cellular WRN trafficking and
activity is regulated by several types of post-translational modifications, which in turn
may be related to a specific DNA damage response pathway.

WERNER SYNDROME (WRN) GENE
The gene known to be defective in WS is located on the short arm of chromosome 8
between positions 12 and 11.2. It was initially localized by linkage analysis, and the use
of markers that were found to be in linkage disequilibrium in WS patients [Goto et al.,
6

1992; Schellenberg et al., 1992; Thomas et al., 1993; Ye et al., 1995]. Finally, it was
identified in 1996 by positional cloning. The discovery of the gene was viewed as
significant, not only because a gene associated with aging was identified, but because it
also turned out to be a cancer susceptibility gene [Yu et al., 1996; Nakura et al., 1996].
The WRN gene spans more than 250 kb and consists of 35 exons (from those, only 34 are
coding exons) that encode a protein of 1,432 amino acids [Yu et al., 1997]. The gene was
cloned by the Martin and Schellenberg groups at the University of Washington, and its
coding sequence immediately suggested a role in DNA metabolism. The existence of 7
conserved sequence motifs, typical of proteins with ATPase and/or helicase activity,
placed WRN in the RecQ helicase family [Yu et al., 1996].

WRN AS A RECQ MEMBER
In general, helicases use the energy derived from the hydrolysis of ATP to catalyze the
unwinding of double-stranded nucleic acids. The RecQ helicases are a subfamily of DNA
helicases that are highly conserved through evolution [Bachrati et al., 2003]. Prokaryotes
and lower eukaryotic species generally contain a single RecQ family member, including
Sgs1 in Saccharomyces cerevisiae and RecQ in Escherichia coli. However, higher
organisms contain multiple RecQ members. The human genome contains at least five
RecQ genes (WRN, BLM, RECQ4, RECQ1, and RECQ5) that encode seven distinct
proteins including three isoforms of RECQ5 generated by alternative splicing [Bachrati et
al., 2008]. All RecQ helicases share a centrally located domain of ~450 residues that
contains the seven conserved helicase motifs (see Figure 1.2). Downstream of the
helicase domain, some RecQ members have additional regions of homology, known as
the RecQ-conserved (RQC) and the Helicase and RNase D C-terminal (HRDC) domains.

7

Figure 1.2 Schematic representations of RecQ family members. The name of the
organisms and the proteins are listed on the right. The proteins are aligned with respect to
their conserved helicase domain (in red). The less conserved RQC and HRDC domains,
discussed in the text, are depicted in yellow and orange, respectively. WRN also contains
an exonuclease domain (in purple) and a 27 residue direct repeat (in light blue). The NLS
sequences are shown in dark blue.

8

In general, loss of function of a RecQ member results in higher levels of illegitimate
recombination, although the resulting types of chromosomal instability can vary
somewhat. Thus, RecQ helicase appear to have prominent roles in the maintenance of
genome stability, although the precise details of their roles in DNA metabolism are still
unknown. Germ-line defects in three of the five human known RecQ helicases are
associated with hereditable diseases. Specifically, defects in WRN, BLM or RECQ4
result in Werner, Bloom or Rothmund-Thomson Syndrome, respectively. Individuals
with these diseases are highly cancer-prone, but those with Bloom and RothmundThomson have fewer aging characteristics than WS patients [Martin et al., 2000].

PROPERTIES OF THE WRN PROTEIN
WRN has an approximate molecular weight of 162 kilodaltons [Chen et al., 2002]. It
has several structural domains (schematically depicted in Figure 1.3) that contribute to its
physiological function. Several laboratories, including ours, have overproduced and
purified recombinant WRN protein and characterized its domains and the basic catalytic
activities associated with them. This section briefly describes each of those domains and
the catalytic activities or properties related with them.
Several studies have demonstrated that WRN possesses DNA-binding activity. In fact,
it has four distinct DNA-binding regions, including the helicase, RQC and HRDC
domains [Liu et al., 1999; von Kobbe et al., 2003; Hu et al., 2005; Lee et al., 2005]. Its
exonuclease domain also possesses DNA-binding affinity, albeit much weaker than the
aforementioned domains [Machwe et al., 2006a]. Importantly, the DNA binding activity
of WRN appears to be dependent upon DNA structure with no apparent nucleotide
sequence preference [Orren et al., 1999; Brosh et al., 2002a]. It has higher affinity to
single-stranded than for double-stranded DNA [Orren et al., 1999], in a manner
influenced by substrate length [Machwe et al., 2006a]. WRN binds most stably, and has
higher affinity, to complex DNA structures including substrates containing bubbles and
D-loops [Orren et al., 2002; Shen et al., 2000; Brosh et al., 2002a].

9

Figure 1.3 Schematic representations of the domains of WRN. The domains of
interest are depicted and identified.
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Consistent with its strong homology to RecQ helicases, the central region of WRN
confers ATPase activity that provides the energy for unwinding DNA with a 3’→5’
directionality [Gray et al., 1997; Suzuki et al., 1997; Shen et al., 1998a]. This unwinding
activity is highly DNA structure-specific in its action. It prefers special DNA structures,
such as those formed during replication and recombination, including forks, bubbles, and
Holliday junction intermediates [Constantinou et al., 2000; Brosh et al., 2001a;
Mohaghegh et al., 2001; Lebel et al., 1999; Orren et al., 2002; Opresko et al., 2004].
Interestingly, our laboratory has demonstrated that, similar to some recombination
proteins, WRN also facilitates the pairing of complementary DNA strands [Machwe et
al., 2005]. This annealing activity acts in concert with its helicase activity to perform
strand exchange, branch migration, and regression of model replication forks
[Constantinou et al., 2000; Machwe et al., 2005, 2006b and 2007]. Thus, these facts
suggest that WRN might be involved in recombination and/or replication-related
pathways to maintain genome stability.
The existence of an N-terminal RNase D-type domain, not present in other human
RecQ members, confers to WRN an intrinsic 3’→5’ exonuclease activity [Huang et al.,
1998; Shen et al., 1998b; Mian et al., 1997]. Thus, the unique premature aging phenotype
of WS may be due to the loss of both helicase and exonuclease functions of WRN in
DNA metabolic pathways. Biochemical analysis of WRN exonuclease activity indicates
that the enzyme prefers the degradation of DNA duplex with a recessed 3’ end and
alternate structures such as an internal bubble, D-loops and Holliday junctions [Orren et
al., 2002; Shen et al., 2000; Machwe et al., 2002]. Interestingly, a recombinant WRN
without the ATPase/helicase domain retains exonuclease activity [Huang et al., 1998],
indicating that the exonuclease domain folds into a functional unit that can be uncoupled
from WRN helicase activity. Although several biochemical studies have examined
possible coordination between the helicase and exonuclease activities of WRN, whether
and how they might act together in vivo remains unclear.
WRN has a direct repeat of a highly acidic 27-amino acid sequence localized between
the region containing the exonuclease and helicase activities. This acid repeat has been
11

shown to be involved in protein-protein interaction such as the WRN and RPA
interaction [Doherty et al., 2005]. The C terminus contains the nuclear localization signal
(NLS). Individuals with WS have WRN gene mutations that truncate the gene product
prior to the NLS. This has lead to the theory that the observed aging phenotypes result
from the total absence of WRN’s nuclear functions.
In summary, WS is a well-established model system for investigating the relationships
between chromosomal instability and development of cancer and other age-related
diseases. At the cellular level, WRN deficiency results in replication abnormalities,
extended S-phase, and hypersensitivity to certain DNA-damaging and replication
blocking agents. In normal cells, subsequent to DNA-damaging treatments or HU, WRN
is recruited to distinct nuclear foci and co-localizes with replication factors. WRN
preferentially acts on complex DNA structures, such as those formed during replication
and recombination. Collectively, this evidence indicates that WRN may play an
important role in response to replication blockage.

RESEARCH OBJECTIVES
Accumulating evidence indicates that WRN has a critical function for maintaining
genomic stability. Consistent with its putative role in DNA metabolism, WRN is
localized in the nucleus. However, upon DNA damage and blockage of replication, WRN
migrates into discrete nuclear foci. These subnuclear foci are sites of ongoing or arrested
DNA replication, supporting WRN function in restoration of blocked replication. In
support of a replication-related role for WRN, it colocalizes with the replication factor
RPA in replication foci. The latter suggests that WRN and RPA might interact at stalled
replication forks, influencing WRN role in accurate resolution of replication blockage.
Importantly, this WRN redistribution correlates with WRN acetylation, suggesting that
this post-translational modification may regulate WRN function at blocked replication
forks. The fact that WRN catalytic activities have preference in resolving unusual DNA
structures and regressing model replication forks are also consistent with a function of
WRN in remodeling or resolving blocked replication forks.
12

The goal of this study is to further clarify the role of WRN in response to agents that
damage DNA and/or block replication, with a particular emphasis on the relationship of
acetylation of WRN with its function in DNA metabolism. The specific hypothesis is that
blockage of replication by DNA damage in the template or other circumstances
(nucleotide depletion, in the case of HU) induces translocation and acetylation of WRN
to perform a key function in proper resolution of these obstructions to replication. In the
absence of WRN, when replication undergoes pausing as in the case of nucleotide
depletion or arrest at the site of DNA damage, the cell cannot properly resolve the
resulting structures. Subsequently, collapse of the replication fork causes double-strand
break formation and increased illegitimate recombination. This is highly consistent with
the increased genomic instability observed in WRN-deficient cells. Thus, to investigate
the events surrounding the potential function of WRN in response to DNA damage and
replication blockage, our studies have been focused on WRN acetylation to determine its
impact on the role of WRN in DNA damage response. The specific aims are: 1) to study
the dynamics of WRN acetylation and its relationship to DNA damage, 2) to investigate
the effect of WRN acetylation on its biochemical functions, and 3) to study if the nature
of WRN interaction with RPA is altered in response to agents that block replication. Our
findings should help to determine an important role for WRN in maintaining genome
integrity and whether and to what extent acetylation of WRN contributes to genomic
integrity surveillance.
This study has addressed the following issues in three chapters:
Chapter 2 – Genotoxin-induced WRN dynamic acetylation and its correlation to blockage
of replication by persistent DNA damage
Chapter 3 – WRN acetylation regulates its enzymatic activities
Chapter 4 –WRN interaction with RPA in response to agents that block replication
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CHAPTER II

GENOTOXIN-INDUCED WRN DYNAMIC ACETYLATION AND ITS
CORRELATION TO BLOCKAGE OF REPLICATION BY PERSISTENT DNA
DAMAGE

INTRODUCTION
DNA damage may induce post-translational modification of proteins to allow proteins
to be regulated in a temporal and spatial manner, in most cases to ensure efficient
regulation of cellular processes in response to genotoxic stress. [Appella et al., 2001;
Huen et al., 2008; Polo et al., 2011]. The most common and well-studied protein
modifications

are

acetylation,

sumolyation,

ubiquitylation,

methylation

and

phosphorylation. The importance of post-translational modification is highlighted by the
results of several recent studies that demonstrate interplay between multiple protein
modifications that combine to propagate the DNA damage signal to elicit cell cycle
arrest, DNA repair, apoptosis and senescence [Huen et al., 2008]. Recent studies have
shown that WRN is subject to post-translational modifications in response to several
DNA damaging agents. Specifically, WRN is subject to acetylation, sumoylation and
phosphorylation [Blander et al., 2002; Karmakar et al., 2002 and 2005; Pichierri et al.,
2003; Yannone et al., 2001]. The work presented here has focused on WRN acetylation
to investigate the impact of this modification on the function of WRN in DNA
metabolism.
First identified for histones over 40 years ago, acetylation of lysine residues of
proteins is now known to occur in more than 80 transcription factors, many nuclear
regulators, and various cytoplasmic proteins. It is emerging as a key mechanism by which
proteins are regulated in several physiological processes such as migration, metabolism
and aging [reviewed on Close et al., 2010 and Choudhary et al., 2009]. In humans, the
acetylation state of proteins is determined by two main groups of enzymes [Figure 2.1].
The first one is the group of histone aceyltransferases (HATs), also called acetylases,
14

Figure 2.1 Protein Acetylation. The acetylation process involves two main groups of
proteins: 1) Acetylases (including GNC5, CBP/p300, PCAF and the MORF complex)
that are responsible for adding the acetyl groups onto lysines in proteins, and 2)
Deacetylases that remove acetyl groups from lysine amino acids. The main ones are the
histone deacetylases (HDACs) and the sirtuins (SIRTs). HDACs are usually found as
multisubunit complexes with proteins containing histone deacetylase and remodeling
activities, such as NURD, and corepressors such as SMRT/NcoR and Sin3.

Copyright © Enerlyn Meliza Lozada Santiago 2011
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that are responsible for adding the acetyl groups onto lysine of proteins. Of these
enzymes, the p300/CBP family is the most characterized and continues to receive the
most attention. The second group of enzymes is known as deacetylases that remove
acetyl groups from lysine amino acids in proteins. The main ones are the histone
deacetylases (HDACs) and the sirtuins that include seven members (SIRT1-7). The
importance of these enzymes is highlighted by the fact that aberrant protein acetylation
and deacetylation activity is associated with various diseases, including solid tumors and
leukemias [Marks et al., 2010; Cress et al., 2000]. Given their association with cancer
formation, novel compounds endowed with a deacetylase inhibitory activity, such as
nicotinamide and Trichostatin A, have gained interest as both cancer chemopreventive
and therapeutic agents [Federico et al., 2011].
It has been demonstrated that acetylation may affect the function of a protein, the
nature of the interaction with its protein partners, and the sub-cellular localization. For
example, acetylation of the genomic guardian and tumor suppressor p53 has been shown
to be induced by DNA damaging agents resulting in alteration of its ubiquitination,
stability and nuclear localization [Liu et al., 1999; Zhao et al., 2006; Chao et al., 2006].
In addition, p53 acetylation regulates the interaction of p53 with its protein partners
(including Mdm2) and its ability to increase transcription of p21 and suppress cell growth
[Tang et al., 2008; Zhao et al., 2006]. Together, these findings indicate that acetylation
can play a key role exerting multifaceted effects to control various cellular and biological
processes in vivo.
Recent studies have shown that the cellular function of WRN appears to be regulated
by acetylation. Specifically, Blander and colleagues reported that WRN acetylation in
vivo is promoted by the acetyltransferase p300 [Blander et al., 2002]. Moreover, it has
been shown that deacetylated WRN is localized in the nucleolus and that acetylation of
WRN correlates with its translocation to nuclear foci (where WRN colocalizes with PML
nuclear bodies that are known to contain protein acetyltransferases); these discrete
subnuclear regions correspond to sites of ongoing and/or blocked DNA synthesis in
which WRN co-localizes with replication factors (such as RPA) in response to DNA
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damaging agents and the replication inhibitor HU [Constantinou et al., 2000; Blander et
al., 2002; Karmakar et al., 2005]. Taken together, it is likely that regulation of WRN
within cells is altered by protein acetylation, and perhaps is related to its function in a
specific DNA metabolic pathway.
In order to further understand the regulation of WRN by protein modification, we
studied the relationship between DNA damage, inhibition of DNA replication and WRN
acetylation. Although some studies indicate potential roles for acetylation in WRN
regulation, it remains unclear the circumstances in which WRN becomes acetylated and
how is WRN specifically regulated by acetylation. In this chapter, we report that WRN is
detectably acetylated under normal conditions and that acetylation of WRN significantly
increases after treatment with DNA damaging agents and inhibitors of DNA replication.
Importantly, we provide evidence that it is not simply the induction of damage but its
persistence that enhances WRN acetylation. The kinetics of WRN acetylation, its cell
cycle relationship and the roles of HDACs and sirtuins in regulation of WRN acetylation
were also investigated.

Together, these studies advance our understanding of the

dynamics of WRN modification in response to DNA damage.

RESEARCH DESIGN

SPECIFIC AIM: To study the dynamics of WRN acetylation and its relationship to
DNA damage.

Aim a. To establish methods to measure endogenous WRN acetylation
Aim b. To investigate the relationship between DNA damage and/or replication
blockage and WRN acetylation
Aim b1. To determine the influence of DNA damaging agents and/or replication
inhibitors on WRN acetylation levels
Aim b2. To examine whether WRN acetylation is directly related to induction of
DNA damage and/or its persistence
Aim b3. To establish the kinetics and cell cycle relationship of WRN acetylation
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Aim c. To study the roles of HDAC and sirtuins deacetylases in regulation of WRN
acetylation

RATIONALE
The cellular function of WRN appears to be regulated by posttranslational
modification [Kusumoto et al., 2007], including acetylation. Consistent with this idea,
WRN modification correlates with its translocation to nuclear foci in response to DNA
damage and replication blockers [Blander et al., 2002; Karmakar et al., 2005]. It is well
established that DNA damage and blockage of replication may induce post-translational
modifications to allow temporal and spatial control over the modified protein
relocalization, interactions and function [Huen et al., 2008; Appella et al., 2001; Polo et
al., 2011]. Collectively, these facts support the notion of an association between WRN
modification and DNA damage and blockage of replication. To further elucidate the
function of WRN in response to DNA damage, we wanted to investigate WRN
acetylation in greater depth. We hypothesized in this study that DNA damaging agents
and replication blocking agents induce WRN acetylation. First, we established a method
to measure acetylation of endogenous WRN (Aim a). Then, we used this method to
analyze if endogenous WRN acetylation is influenced in response to DNA damaging
agents and replication inhibitors (Aim b1). If our hypothesis is true, increasing the
frequency of damage should lead to increased levels of WRN acetylation.
Experimentally, this can be accomplished by preventing removal of damage by standard
repair pathways to determine if WRN acetylation is amplified after appropriate DNA
damage when the DNA repair pathway involved in removing the induced damage is
absent and/or defective (Aim b2). Since lysine acetylation is a reversible posttranslational
process that could be related to detection and propagation of specific cellular responses
[Huen et al., 2008], we analyzed the kinetics and potential relationship to cell cycle (Aim
b3). Given that lysine acetylation is governed by the opposing actions of
acetyltransferases and deacetylases, we analyzed the role of deacetylases in regulation of
WRN acetylation (Aim c). Specifically, we studied whether WRN is a substrate for the
activity of HDAC and sirtuin classes of deacetylase enzymes.
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Aim a. To establish methods to measure endogenous WRN acetylation. Although
expression systems have been use to examine acetylation of proteins, including WRN, the
detection of endogenous acetylated WRN requires additional challenges and optimization
of protocols to achieve high sensitivity. Thus, we established our own protocol to obtain
better sensitivity and provide quantitative data. This was accomplished by analyzing the
specificity of different commercially available antibodies against WRN and acetylated
lysine residues in proteins during immunoprecipitation and immunoblotting techniques.
The utility and validation of the approach was assessed by using purified wild-type and
acetylated WRN.

Aim b. To investigate the relationship between DNA damage and/or replication
blockage and WRN acetylation. WRN-deficient cells are hypersensitive to several
DNA damaging agents, including methylmethanesulfonate (MMS), mitomycin C (MMC)
and cisplatin, and the replication inhibitor hydroxyurea (HU) [Poot et al., 2001; Imamura
et al., 2002; Harrigan et al., 2006]. Since WRN function is needed for resistance to these
agents, then it might be regulated in response to these treatments, including by posttranslational modification. As support for this idea, in normal cells WRN relocalizes from
(primarily) the nucleolus to punctuate nuclear foci (also containing replicator factors)
following treatment with MMS and DNA replication inhibitors [Karmakar et al., 2005;
Constantinou et al., 2000]. This movement of WRN to nuclear foci correlates with WRN
modification, specifically with WRN phosphorylation and acetylation [Pichierri et al.,
2003; Blander et al., 2002].
Since WRN cells are hypersensitive to MMS, MMC, cisplatin and HU, we used these
agents to produce DNA damage or maximally block replication for the subsequent
examination of WRN acetylation (aim b1). To determine if WRN acetylation is indeed
related to DNA damage, we studied whether WRN modification is increased in cells with
deficient or inhibited repair pathways after appropriate DNA damaging treatments (aim
b2). Since cells with deficient or inhibited repair pathways cannot repair the lesions
caused by specific DNA damaging agents, the damage will persist. If DNA damage
results in WRN acetylation, then disabling specific DNA repair pathways should amplify
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WRN acetylation. Thus, this strategy should help to establish whether the effect of the
agent is specifically mediated by the DNA damage that it generates and to examine
whether the response (acetylation) is related to initial damage induction or to the
persistence of the DNA damage. If the latter is the case, this may imply a downstream
effect of the damage on DNA metabolism.
Acetylation is a reversible posttranslational modification [Yang et al., 2004]. Thus, to
establish the kinetics of WRN acetylation (aim b3), we studied the rate at which WRN is
acetylated and the duration of this modification on WRN. To this end, WRN acetylation
was monitored at several time points after MMS treatment. Importantly, such
experiments should help to determine the kinetics of WRN acetylation as a function of
time. It has been shown that protein acetylation status could be associated with (events
occurring during) specific cell cycle phases. For example, PCNA acetylation has been
shown to be related to S phase progression [Naryzhny et al., 2004]. Thus, as part of this
study, we also sought to identify if WRN acetylation is associated with a specific phase
of the cell cycle. This relationship was analyzed first by comparing the cell cycle profile
of population of cells untreated or treated with a DNA damaging agent that induced
WRN acetylation. The efficacy of the experiment was verified by flow cytometry
following Hoechst staining of permeabilized cells. Then, to analyze if WRN acetylation
has a relationship to DNA replication (or the lack thereof), DNA synthesis in the
presence and absence of DNA damaging agents or replication inhibitors was directly
measured by bromodeoxyuridine (BrdU) incorporation, a synthetic thymidine analog
that gets incorporated into a cell’s DNA during replication.

Aim c. To study the roles of HDAC and Sirtuin deacetylases in regulation of WRN
acetylation. The acetylation state of a protein is determined by the opposing action of
acetylases and deacetylases. In this aim, we investigate the role of deacetylases in
regulating WRN acetylation. To date, eighteen genes encoding proven or putuative
deacetylases have been identified in humans [Johnstone et al., 2002; Witt et al., 2009].
These have been divided into four distinct classes based on based on their size, cellular
localization, number of catalytic active sites, and homology to yeast HDAC proteins.
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Class I, II, and IV are called the ‘‘classical” HDACs and Class III is known as sirtuins
[Witt et al., 2009]. Therefore, we used drugs to inhibit the different classes of
deacetylases: trichostatin A (TSA) selectively inhibits the Class I, II and IV of histone
deacetylase enzymes and nicotinamide has been shown to inhibit the Class III that are the
sirtuins [Moradei et al., 2005; Bieliauskas et al., 2008; Walkinshaw et al., 2008; Cen et
al., 2010; Witt et al., 2009]. These inhibitors were used alone and in combination, as well
as with DNA damaging agents, to investigate the dynamics of WRN acetylation and the
roles of each class of deacetylases.

METHODS
Culture medium and reagents. The SV40-transformed fibroblast cell lines, 1-O and 8D, used in my experiments were obtained from J. Christopher States, University of
Louisville. Methylmethanesulfonate (MMS), phenylmethylsulfonylfluoride (PMSF),
TSA, nicotinamide, HU, MMC, cisplatin, O6-benzylguanine and protease inhibitor
cocktail were purchased from Sigma-Aldrich. Olaparib was purchased from ChemieTek.
Cell culture media and reagents were purchased from Invitrogen. Cells were grown in
MEM-α Glutamax medium supplemented with 10% FBS, 1% HEPES, and 1% penicillinstreptomycin at 37°C in a humidified atmosphere containing 5% CO2. For DNA
damaging treatments, we chose MMS, MMC, and cisplatin. We also used the replication
inhibitor HU. After we chose these drugs for our experiments, we initially treated
actively growing, subconfluents populations of cells with doses reported from other
studies representing physiological conditions. Then, we monitored toxicity by counting
viable cells to establish the proper dose range to work. Cells were incubated in growth
medium containing 1 mM MMS for 4 h, 2 mM HU for 16 h (or 10 h when indicated), 7
µM MMC for 16 h or 25 µM cisplatin for 19 h before harvesting. For inhibition of
deacetylases, cells were incubated in growth medium containing 1 µM TSA and/or 5 mM
nicotinamide for 4 h or 10 h (as indicated in figures) in the presence or absence of MMS
or HU. For inhibition of MGMT, cells were pre-incubated in growth medium containing
40 µM O6-benzylguanine for 4 h followed by incubation with 1 mM MMS for an
additional 4 h. For treatment with O6-benzylguanine alone, cells were treated with 40 µM
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O6-benzylguanine for 8 h. To study the inhibition of PARP, cells were treated with 5 nM
olaparib for 38 h followed by incubation with 1 mM MMS for an additional 4 h. For
treatment with olaparib alone, cells were treated with 5 nM olaparib for 42 h.
Expression and purification of unmodified and acetylated WRN. Purified WRN
proteins (unmodified and acetylated) were used for optimization of immunoprecipitation
methods as well as for enzymatic studies (conducted as described in Chapter III).
Recombinant unmodified WRN was expressed using the baculovirus-insect cell system
as described [Orren et al., 1999]. FLAG-tagged WRN and FLAG-tagged acetylated WRN
were overexpressed in HEK293 cells using a transient transfection assay (developed by
Dr. Jianyuan Luo, University of Maryland Medical School). To obtain unmodified
FLAG-WRN, cells were transfected with vector specifying production of FLAG-WRN.
To obtain acetylated WRN, cells were co-transfected with individual vectors specifying
production of FLAG-WRN and CMV-p300 or CMV-CBP (p300 and CBP are two
acetyltransferases that acetylate WRN in vivo) [Blander et al., 2002]. To maximally
acetylate WRN protein, cells were treated with TSA and nicotinamide to inhibit cellular
deacetylase activity 6 h before harvest. To obtain deacetylated FLAG-WRN, cells were
co-transfected with FLAG-WRN, CBP and SIRT1 (a histone deacetylase) vectors. Cells
were harvested 36 h after transfection and were lysed in a FLAG-lysis buffer (50 mM
Tris-HCl pH 7.8, 137 mM NaCl, 1 mM NaF, 1 mM NaVO3, 1% Triton X-100, 0.2%
Sarkosyl, 1 mM DTT, 10% glycerol) containing fresh protease inhibitors, PMSF, 10 µM
TSA and 5 mM nicotinamide. After anti-FLAG M2 immunoprecipitation, the
immobilized FLAG-WRN proteins were released using FLAG peptide (Sigma) and
purified unmodified or acetylated FLAG-WRN was collected. To determine relative
protein concentration, the eluted protein products were resolved by 8% SDS-PAGE gels
and analyzed by western blot with anti-WRN antibody (Santa Cruz Biotechnology). To
determine the level of acetylation, the products were analyzed by western blot with antiacetylated lysine antibody (Cell Signaling).
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Immunoprecipitation and detection of WRN acetylation. For immunoprecipitation
experiments, cells were lysed by sonication in RIPA buffer (50 mM Tris-HCl (pH 7.4),
150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, and 1 mM EDTA) supplemented
with protease inhibitor cocktail, 1 mM PMSF and 10 units/ml of DNase I (New England
Biolabs). After centrifugation at 21,000  g for 12 min at 4°C, the supernatants/clarified
lysates were isolated and their protein concentrations measured. Aliquots of the clarified
lysates (~600 ug of protein each) were then pre-cleared with Protein G Plus/Protein A
agarose beads (Calbiochem) and 1 ug of normal mouse IgG (Santa Cruz) for 1 h, then
incubated with anti-acetylated lysine antibody (Cell Signaling) and 30 μl of Protein G
Plus/Protein A bead suspension for 18 h at 4°C. After collection by centrifugation and
removal of supernatant, the beads were then washed three times with RIPA buffer
supplemented with protease cocktail inhibitors, 1 mM PMSF and 200 ug/ml ethidium
bromide. After removal of the final wash, equal portions of RIPA and 2X SDS sample
buffer were added to the beads and immunoprecipitated proteins were released by heating
at 95°C for 5 min. Equal volumes of each sample were resolved by SDS-PAGE (8%). For
the loading control, 30-50 ug of each sample (as specified in figures) were also resolved
by SDS-PAGE (8%). Proteins were transferred to PVDF membranes (Bio-Rad) by
electroblotting. The membranes were blocked with 5% nonfat dry milk in TBST buffer
(20 mM Tris, pH 7.4, 140 mM NaCl and 0.1% Tween-20) and analyzed by western
blotting with mouse monoclonal anti-WRN (Abcam) antibody for 18 h at 4°C followed
by incubation with peroxidase-labeled secondary anti-mouse (GE Healthcare) for 1 h at
room temperature. Signal was visualized by chemiluminescent analysis using ECL Plus
(GE Healthcare).
Micronucleus Assay. 8-D and 1-O cells were incubated in growth medium without or
with 25 µM Cisplatin for 19 h. After 19 h incubation, the media was removed and cells
were washed twice with growth medium. New media was added to the cells and
cytochalasin B (3 ug/mL, from Sigma-Aldrich) was added to the culture for 24 h. Cells
were harvested, fixed (methanol:acetic acid 3:1) at 4°C and seeded onto microscope
slides (75 x 25 mm, 1 mm thick from Fisher Scientific). Slides were air dried, then
stained with a 10% Giemsa (Sigma-Aldrich) solution and examined at 1000×
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magnification (oil) using a bright field microscope. One thousand (1000) binucleated
cells per treatment were examined and the number of micronuclei was recorded.

Flow Cytometry Analysis. 1-O cells were incubated in growth medium containing +/- 1
mM MMS for 2 h. After incubation, cells were harvested and counted using a
hemocytometer. Cells were suspended at a density of 5 × 106 cells/ml in sorting buffer
[1× PBS (Ca/Mg++ free), 1 mM EDTA, 25 mM HEPES pH 7.0, 1% FBS (heat
inactivated)]. Hoechst 33342 stain (10 µM, from Sigma-Aldrich) was added and cells
were incubated at 37°C for 45 min (with mixing every 5 min). Cells were filtered thru a
40 micron cell strainer (from Fisher Scientific) to remove clumps and debris. Cells were
analyzed by flow cytometry and subsequently subjected to immunoprecipitation and
immunoblotting as specified above.
BrdU incorporation Assay. The assay was performed using a kit following the
manufacturer instructions (Exalpha Biologicals BrdU cell proliferation assay). A
suspension of 1-O cells (1.5 × 105 cells/ml) was prepared using culture media. 100 ul was
added to each well (using 96-well tissue culture plates). After 8 h, cells were untreated,
treated with 2 mM HU for 16 h, or treated with 1 mM MMS for 1-4 h (as indicated in
figures). BrdU was added 1 h prior to the end of the treatments. Media was aspirated
from the cell wells and cells were fixed (using a solution provided in the kit) at room
temperature for 30 min. Cells were washed three times using the washing buffer provided
by the manufacturer. An anti-BrdU monoclonal antibody was added and cells were
incubated for 1 h at room temperature. Cells were washed three times and incubated for
30 min at room temperature with peroxidase goat anti-mouse IgG conjugate. After three
washes, TMB (3,3', 5,5"-tetramethylbenzidine) peroxidase substrate was added and cells
were incubated for 30 min at room temperature in the dark. A stop solution was added to
every well and the absorbance was measured at 450 nM using a spectrophotometric
microtiter plate reader (SpectraMax Plus 384, Molecular Devices).
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Statistical analysis. The data was analyzed using one-way ANOVA followed by
Newman Keuls post-test (GraphPad Prism-4). A p value of less than 0.05 was considered
a significance difference.

RESULTS
Protocol for detection of endogenous acetylated WRN. Previous studies show WRN
modification and relocalization to nuclear foci after treatment with DNA damaging
agents and blockers of replication. In light of these findings, we reasoned that it should
be possible to detect WRN modification, specifically WRN acetylation, particularly as a
response to DNA damage and replication stress. Although experimental approaches exist
to tease out the role of post-translational modifications on WRN, most of them have been
based on ectopic expression of WRN. Because of a lack of methods and information on
endogenous WRN modifications, we set out to establish our own protocol to measure
endogenous WRN acetylation. First, we tested the specificity of different commercially
available antibodies against WRN protein to detect unacetylated and acetylated WRN
protein, produced as described in the Methods section. Then, we tested the ability of
those antibodies to pull WRN from cell lysates. The specificity of different commercially
available antibodies against acetylated lysine proteins (including an antibody against
acetylated WRN) was also tested to determine if they can recognize purified acetylated
FLAG-WRN protein. The capability of those antibodies to pull down acetylated WRN
and their specificity was also established by adding purified acetylated WRN into cell
lysates of WRN-deficient and -proficient cell lines. Finally, we tried different
combinations of the antibodies to perform IP and immunoblotting techniques. From all
the combinations tested, we decided to use an antibody against acetylated lysine for the
IP reaction and an antibody against WRN to probe for acetylated WRN since that
combination of antibodies gave us clean, consistent and highly sensitive western blots.
Importantly, the selected antibody against WRN was able to identify both states
(unacetylated and acetylated) of WRN (Figure 2.2A) and the antibody against acetylated
lysine specifically recognizes the acetylated form of WRN (Figure 2.2B). In addition, the
acetylated lysine antibody specifically pulled down the acetylated form of WRN (Figure
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Figure 2.2 Specificity of antibodies selected for our studies. A) Unacetylated and
acetylated recombinant WRN proteins were subjected to SDS-PAGE and Western
blotting with anti-WRN antibody. B) Unacetylated and acetylated recombinant WRN
proteins were subjected to SDS-PAGE and Western blotting with anti-acetylated lysine
antibody. C) Cell lysates were subjected to immunoprecipitation by incubating with the
specified antibodies (Ab) in the presence or absence of purified acetylated WRN. The IP
products were subjected to SDS-PAGE and analyzed by Western blotting with anti-WRN
antibody.
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2.2C, compare lanes 3 and 4). The diagram in figure 2.3 shows the established protocol.
Briefly, after drug treatments, cell lysates were prepared and the protein concentration of
each cell lysate was measured to use comparable amounts of each sample. Lysates were
subject to a pre-clearing step to remove proteins that interacted non-specifically with
normal IgG and Protein G Plus/Protein A beads. The pre-cleared lysates were incubated
with a mouse monoclonal antibody against acetylated lysine to immunoprecipitate the
pool of acetylated proteins. After release from the beads, immunoprecipitated proteins
were separated by SDS-PAGE and analyzed by Western Blot using an antibody specific
for WRN protein. The results were quantified using a fluorimager.
DNA damaging agents/replication inhibitors enhance WRN acetylation. WS cells are
hypersensitive to certain DNA damaging agents, including MMS, MMC and cisplatin. In
addition, WS cells are hypersensitive to the replication inhibitor HU. Collectively, these
findings suggest that WRN might be regulated in response to those treatments, including
by post-translational modifications. Thus, we used these agents as possible candidates for
the induction of WRN acetylation. As a negative control, cells were analyzed after UV-C
irradiation, a treatment that does not cause enhanced cell death in WS cells compared to
normal cells. MMS is a DNA-alkylating agent that methylates DNA bases, producing 7methylguanine, 3-methyladenine and O6-methylguanine [Wyatt et al., 2006]. MMC is a
crosslinking agent that induces interstrand crosslinks [Dusre et al., 1989]. Cisplatin is a
platinum-based chemotherapy drug that acts by generating mostly intrastrand crosslinks,
repaired by nucleotide excision repair (NER), as well as some interstrand crosslinks
[Jamieson et al., 1999]. HU depletes nucleotide pools by inhibition of the enzyme
ribonucleotide reductase, resulting in blocking progression of all replication forks [Skog
et al., 1992]. WS cells are hypersensitive to HU, apparently by apoptosis of cells with
stalled replication forks [Pichierri et al., 2001]. UV-C causes direct photochemical
damage to DNA producing covalent linkages between adjacent cytosine and thymidine
bases creating cyclobutane pyrimidine dimers and 6-4 photoproducts [Sinha et al., 2002;
Markovitsi et al., 2010]. Experiments were performed with human fibroblasts treated
either with or without 1 mM MMS for 4 h, 2 mM HU for 16 h, 7 µm MMC for 16 h, 25
µM cisplatin for 19 h or irradiated with 20 J/m2 or 40 J/m2 UV-C. Interestingly, a low
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Figure 2.3 Schematic representation of the protocol used.
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level of acetylation of WRN is detectable even in untreated cells (Figure 2.4A, lane 2).
More importantly, the amount of acetylated WRN is significantly increased in cells
treated with MMS, HU, MMC, and cisplatin (Figure 2.4A, upper panel, compare lines 2
to 3-6). Quantitation of data from multiple independents experiments indicates that
treatment with MMS results in 3.3 fold increase and treatment with HU in 2.1 fold
increase in the levels of WRN acetylation. The crosslinking agents also increase the
levels of acetylated WRN, since treatment with MMC and cisplatin resulted in 2.7- and
2.5-fold increase (quantitation in Figure 2.4B), respectively. This effect was not due to an
increase in WRN expression or abundance caused by any of the treatments, since a
parallel Western analysis of lysates with anti-WRN antibody indicated that the same
amount of total WRN is present following each treatment (Figure 2.4A lower panel). In
contrast, irradiation of cells with 20 J/m2 or 40 J/m2 UV-C does not increase significantly
the levels of acetylated WRN (Figure 2.4C, compare line 2 vs. lines 3 and 4, quantitation
on figure 2.4D). Collectively, this data indicates that WRN acetylation is upregulated in
response to certain DNA damaging treatments (but not UV) and replication inhibitors.
Correlation between persistent DNA damage and WRN acetylation. Although the
experiments above suggest an association between DNA damage and WRN acetylation in
vivo, we wanted to confirm this relationship and investigate it further. Our strategy was to
inhibit removal of particular types of DNA damage to increase the frequency of those
lesions in the DNA template. If WRN acetylation is related to DNA damage, inhibition of
repair pathways that remove the relevant type of damage should amplify the effect of the
damaging agent on WRN acetylation. Thus, we monitored WRN acetylation in cells with
normal and compromised repair pathways after appropriate DNA damaging treatments.
Initially, we focused on MMS because this agent gave us the highest increase in WRN
acetylation. MMS methylates DNA at the N7-deoxyguanine, N3-deoxyadenine and O6deoxyguanine positions. Thus, we examined the effect of persistence of these adducts on
WRN acetylation. The 7-methylguanine and 3-methyladenine adducts are repaired by
base excision repair (BER) [Wyatt et al., 2006]. BER is involved in repair of DNA
damage arising from spontaneous base loss or genotoxic agents that modify bases, such
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Figure 2.4 WRN is acetylated in response to DNA damaging agents/replication
inhibitors. A) 8-D cells were incubated in growth medium with or without 1 mM MMS
for 4 h, 2 mM HU for 16 h, 7 uM MMC for 16 h or 25 uM Cisplatin for 19 h (before
harvest) and clarified cell lysates were processed for IP with anti-acetylated lysine
antibody. The IP products were subjected to SDS-PAGE and western blotting with antiWRN antibody (upper panel). 50 ug of each cell lysate were subjected to SDS-PAGE and
western blotting with anti-WRN antibody (lower panel) to ensure that equal amount of
total WRN was present in the IP reactions as control. B) Quantitative bar graph for WRN
acetylation (mean ± SEM of 3 independent experiments. * = P < 0.05 when compared
with control untreated cells). C) Cells were irradiated (20 J/m2 or 40 J/m2 UV-C) or
treated with 1 mM MMS for 4 h (before harvest) for IP with anti-acetylated lysine
antibody. The IP products were subjected to SDS-PAGE and Western blotting with antiWRN antibody (upper panel). 40 ug of each cell lysate were subjected to SDS-PAGE and
Western blotting with anti-WRN antibody (lower panel). D) Quantitative bar graph for
WRN acetylation (mean ± SEM of 4 independent experiments. * = P < 0.05 when
compared with control untreated cells). Lanes 1 in figure A and C are purified acetylated
WRN (upper panel) or purified unmodified WRN (lower panel) that we used as marker
(MKR).
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as MMS [Wyatt et al., 1999 and 2006; Horton et al., 2005]. The O6-methylguanine
adducts are acted on by the enzyme O6-methylguanine methyltransferase (MGMT) that
repairs O6-methylguanine by direct transfer of the alkyl group on guanine to a
cysteineresidue in its active site [Gerson et al., 2002; Kaina et al., 2007]. Thus, we used
the drugs O6-benzylguanine and olaparib to inhibit the repair of the DNA lesions
produced by MMS. The agent O6-benzylguanine is a potent inactivator of MGMT by
acting as a substrate for the protein. Specifically, MGMT transfers the benzyl group in
O6-benzylguanine to the cysteine residue in the active site of the protein resulting in
MGMT inactivation and, therefore, lesions present at the O6 position of DNA induced by
MMS remain unrepaired [Dolan et al., 1990 and 1997; Murakami et al., 2007]. First, cells
were pre-treated with O6-benzylguanine for 4 h before the addition of MMS for an
additional 4 h. Interestingly, co-treatment of cells with MMS and O6-benzylguanine did
not appear to increase WRN acetylation (Figure 2.5A, upper panel, compare lines 3 and
4). Quantitation of data from multiple independent experiments is shown in Figure 2.5B.
This result suggests that O6-methylguanine lesions are not responsible for triggering
WRN acetylation.
Then, we followed a similar strategy as above but using olaparib that inhibits the
enzyme poly (ADP-ribose) polymerase (PARP) and consequently BER. Olaparib is an
analog of the substrate NAD+ that binds to the catalytic site of PARP [Plummer et al.,
2006; Lord et al., 2008]. PARP is involved in BER by binding gaps and nicks in DNA
and helping to open up the damaged DNA to allow access to other components of the
repair process [Petrucco et al., 2003]. Specifically, olaparib inhibits PARP by preventing
its automodification that is necessary for its release from DNA and the recruitment of
proteins involved in BER [Horton et al., 2005]. Importantly, olaparib is not cytotoxic at
concentrations necessary to achieve PARP inhibition [Cepeda et al., 2006]. Interestingly,
co-treatment of cells with MMS and olaparib further increased WRN acetylation (Figure
2.5C, upper panel, compare lines 3 and 4). The increase in WRN acetylation was not due
to olaparib treatment since the cells treated with olaparib alone had comparable amounts
of acetylated WRN as control untreated cells (Figure 2.5C, upper panel, compare lines 2
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Figure 2.5 Correlation between DNA damage and WRN acetylation. A) 8-D cells
were incubated in growth medium with or without 40 µM O6-Benzylguanine (O6-BG) for
4 h followed by incubation with 1 mM MMS for an additional 4 h. For treatment with O6BG alone, cells were treated with 40 µM O6-BG for 8 h. Cells were harvested and
subjected to IP with anti-acetylated lysine antibody and immunobloting with anti-WRN
antibody (upper panel). 40 ug of each cell lysate were subjected to SDS-PAGE and
Western blotting with anti-WRN antibody (lower panel). B) Quantitative chart for WRN
acetylation (mean ± SEM of 3 independent experiments. * = P < 0.05 when compared
with control untreated cells). C) 8-D cells were incubated in growth medium with or
without 5 nM Olaparib for 38 h followed by incubation with 1 mM MMS for an
additional 4 h. For treatment with Olaparib alone cells were treated with 5 nM Olaparib
for 42 h. Cells were harvested and subjected to IP with anti-acetylated lysine antibody. IP
products were analyzed by immunoblotting with anti-WRN antibody (upper panel). 60 ug
of each cell lysate were analyzed by Western blotting with anti-WRN antibody (lower
panel). D) Quantitative chart for WRN acetylation (mean ± SEM for two independent
experiments. * = P < 0.05 when compared with control, and # = P < 0.05 when compared
with cells treated with MMS alone). Lanes 1 in figure A and C are purified acetylated
WRN (upper panel) or purified unmodified WRN (lower panel) that we used as marker
(MKR).
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and 5). Quantitation of data from multiple independent experiments indicates that cotreatment with MMS and the PARP inhibitor increases WRN acetylation by 4.1 fold,
compared to a 3.1 fold increase for MMS treatment alone (Figure 2.5D). These results
suggest that persistence of 7-methylguanine and 3-methyladenine lesions induce a further
amplification of WRN acetylation.
Our previous results show that WRN is acetylated after cisplatin treatment. Cisplatin
primarily produces bulky DNA adducts repaired by nucleotide excision repair (NER)
[Sancar et al., 1995; Wang et al., 2001; Zheng et al., 2003]. Therefore, NER-deficient cell
lines provide opportunities to examine the effects of persistent DNA damage generated
by cisplatin on WRN acetylation. Experiments were performed by comparing WRN
acetylation after 19 h cisplatin treatment in NER-proficient (8-D cells, normal NER+)
and NER-deficient (1-O cells, NER- since they are XPA-deficient) human fibroblasts. As
shown in Figure 2.6A, WRN acetylation is further amplified in NER-deficient cells after
cisplatin treatment when compared with NER-proficient cells (upper panel, compare lines
3 and 5). This increase is not due to a difference in WRN expression levels between the
cell lines, since a parallel Western analysis of samples using an anti-WRN antibody
indicated that approximately the same amount of total WRN is present (Figure 2.6A,
lower panel). In addition, the levels of acetylated WRN in the untreated 1-O and 8-D cell
lines are comparable (Figure 2.6A, upper panel, compare lines 2 and 4). Quantitation of
data from multiple independent experiments indicates that WRN acetylation in NERproficient cells was higher (2.2 fold) when they are treated with cisplatin as compared to
their control untreated. However, this difference increases when NER is defective; i.e.,
when NER-deficient cells are treated with cisplatin, the difference was 3.8 fold when
compared to their untreated control (Figure 2.6B). Therefore, these experiments indicate
that WRN acetylation corresponds to DNA damage generated by cisplatin and is
amplified by the persistence of lesions subject to NER.
To ensure that indeed NER-deficient cells lines have lower efficiency in their DNA
repair system, and be confident in the correlation that WRN acetylation increases with
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Figure 2.6 WRN acetylation is amplified as a result of persistent DNA damage. A)
8-D (NER+) and 1-O (NER-) cells were incubated in growth medium with or without 25
uM cisplatin for 19 h before harvest for IP with anti-acetylated lysine antibody. The IP
products were subjected to SDS-PAGE and Western blotting with anti-WRN antibody
(upper panel). 60 ug of each cell lysate were subjected to SDS-PAGE and Western
blotting with anti-WRN antibody (lower panel). Lanes 1 is purified acetylated WRN (upper
panel) or purified unmodified WRN (lower panel) that we used as marker (MKR).

B)

Quantitative bar graph for WRN acetylation (mean ± SEM. of 4 independent
experiments. * = P < 0.05 when compared with control untreated cells, and # = P < 0.05
when compared with NER Proficient cells treated with Cisplatin). C) To measure
micronucleus (MN) formation, 8-D cells and 1-O were incubated in growth medium with
or without 25 uM Cisplatin for 19 h. Cells were washed twice with growth medium and
cytochalasin B (3 ug/mL) was added to the culture for 24 h. Cells were harvested, fixed
(methanol:acetic acid 3:1) and stained with a 10% giemsa solution. D) Quantitative bar
graph for frequency of MN formation in binucleated (BN) cells.
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persistence of DNA damage generated by cisplatin, we employed the cytokinesis-block
micronucleus assay that measures genome instability that is a consequence of DNA
damage. In this technique, genomic instability is scored specifically by counting
micronuclei that are biomarkers of chromosome breakage and/or chromosome loss, in
binucleated cells [Fenech et al., 2007 and 2008]. The binucleated appearance of cells is a
result of blocking cytokinesis with cytochalasin-B, an inhibitor of microfilament ring
assembly required for the completion of cytokinesis. Trapping cells at this stage
maximizes detection of chromosome breakage. Higher number of micronuclei is
indicative of higher chromosome damage. Briefly, NER-proficient and NER-deficient
cells were incubated with or without cisplatin for 19 h, following incubation with
cytochalasin-B for 24 h. Cells were harvested, fixed and stained and the number of
micronuclei formed was scored. The results indicate that, indeed, the NER-deficient cell
line had higher numbers of micronuclei formed (scoring in Table 2.1) after the cisplatin
treatment when compared with the NER-proficient cell line (see Figure 2.6C).
Calculation of the frequency of micronuclei formed in NER-proficient and deficient cell
lines indicate that cisplatin treatment induces higher levels of micronuclei formation in
the NER-deficient cells when compared to NER-proficient cells (0.412 vs. 0.227
micronuclei/binucleated cells, respectively). Quantitation is shown in Figure 2.6D. Thus,
the increased frequency of micronuclei in NER-deficient cells following cisplatin
treatment indicates these cells maintain a larger burden of DNA damage and support the
notion that they are deficient in repair of cisplatin-induced lesions. Collectively, our
results support the notion that WRN acetylation is amplified as a result of inhibition of
repair of cisplatin lesions by NER and of 3-methyladeninde and/or 7-methylguanine
lesions by BER.
Kinetics and cell cycle relationship of WRN acetylation. Lysine acetylation could be
related to specific cellular responses during the individual cell cycle phases [Huen et al.,
2008]. Therefore, we examined whether WRN acetylation is associated with a particular
cell cycle phase. Initially, we tried cell cycle synchronization protocols by serum
starvation and contact inhibition to verify if the levels of WRN acetylation are enriched in
any specific phase of the cell cycle. However, the purity and amount of cells obtained in
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CELL LINE

TREATMENT

BN CELLS
COUNTED
1000

# MN
FOUND
52

FREQUENCY

8-D Cells
(NER Proficient)

0.052

-

8-D Cells
(NER Proficient)
1-0 Cells
(NER Deficient)

25 uM Cisplatin

1000

227

0.227

-

1000

48

0.048

1-0 Cells
(NER Deficient)

25 uM Cisplatin

1000

412

0.412

Table 2.1 Frequency of MN formation in NER proficient and deficient cell lines.
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the synchronized populations were not suitable for our purposes. To obtain enriched
population of cells, we also tried to sort the cells in the different cell cycle phases.
However, the percentage of recovered cells (especially in G2) was not enough for our
purposes. Thus, we analyzed and compared the cell cycle profile of a population of
untreated cells with a population of cells treated with MMS, the treatment that induces
the highest levels of WRN acetylation. As seen in Figure 2.7, untreated cells showed a
relatively normal asynchronous profile. However, in MMS treated cells, we can see an
increase in the percentage of cells at S-phase and a loss of G2/M phase cells. In parallel
with flow cytometry experiments, acetylated WRN was immunoprecipitated from cells
using an acetylated lysine antibody and the IP products were subsequently analyzed by
immunoblotting with an anti-WRN antibody. Again, WRN acetylation increases after the
MMS treatment, suggesting that WRN acetylation correlated with the increase in S-phase
cells (Figure 2.7).
Although the experiments above suggest a correlation between S-phase progression
and WRN acetylation in vivo, we wanted to corroborate this relationship and investigate
it further. Thus, to determine if indeed WRN acetylation correlates with S-phase or
replication blockage, the effect of our treatments on DNA replication was established.
To this end, the incorporation of bromodeoxyuridine (BrdU) was measured. BrdU is a
synthetic thymidine analog that is incorporated during DNA synthesis. Experiments were
performed with cells treated either with or without 1 mM MMS for 4 h or 2 mM HU for
16 h. BrdU incorporation was measured using the protocol described in the Methods
section. Interestingly, the incorporation of BrdU was abolished (non-detectable) in HUand MMS-treated cells when compared with untreated cells, indicating that these HU and
MMS treatments dramatically inhibit DNA replication. Taken together, this evidence
suggests that acetylation of WRN observed after HU and MMS correlates with blockage
of replication during S-phase.
To gain further insight on WRN acetylation in response to induced DNA damage, we
investigated the kinetics of WRN acetylation to determine the timing of the onset of
acetylation and the duration of this modification. For these experiments, cells were
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Figure 2.7 WRN acetylation is associated with S-phase progression. A) Cells were
incubated in growth medium with or without 1 mM MMS for 2 h before harvest for
Hoechst staining. Cells were analyzed by flow cytometry and subsequently subjected to
immunoprecipitation with anti-acetylated lysine antibody. The IP products were
subjected to SDS-PAGE and Western blotting with anti-WRN antibody (upper panel). 30
ug of each cell lysate were subjected to SDS-PAGE and Western blotting with anti-WRN
antibody (lower panel) to ensure that equal amount of total WRN was present in the IP
reactions as control. Lanes 1 is purified acetylated WRN (upper panel) or purified
unmodified WRN (lower panel) that we used as marker (MKR).
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incubated with MMS (since this treatment produced the highest level of acetylated WRN)
and harvested at different time points (1 h, 2 h, 4 h). We also analyzed cells 2 h and 4 h
after MMS treatment (by removing medium containing MMS and replacing it with fresh
medium). After lysis, acetylated WRN was immunoprecipitated as previously and
resolved by SDS-PAGE to compare the levels of WRN acetylation at the different time
points. As seen in Figure 2.8A, WRN acetylation starts to increase gradually after 1 h,
reaching its maximum level of acetylation after 4 h. However, at a later time, specifically
4 h after removal of MMS, the levels of acetylated WRN decrease to normal levels
(quantitation on Figure 2.8B). Thus, the increase in WRN acetylation levels seems to be a
transient regulatory process for WRN. We also measured the incorporation of BrdU at the
different time points. Upon treatment with 1 mM MMS, BrdU incorporation dropped to
29% of the untreated control by 1 h, and to undetectable levels thereafter. Thus, the
timing of the increase in WRN acetylation after MMS roughly corresponds to its
inhibitory effect on DNA replication.
Role of HDAC and sirtuins in regulation of WRN acetylation. Modulation of protein
acetylation depends upon the opposing activities of acetylases and deacetylases. As the
name implies, deacetylases remove acetyl groups from the side chain of specific lysine
residues on proteins. Eighteen isoforms of mammalian deactylases have been described
so far [Walkinshaw et al., 2008]. They have been grouped into two families and four
classes. The HDAC family, also known as the classical family, is composed of Class I, II
and IV. The sirtuin family is composed of Class III. The two families have entirely
different catalytic mechanisms of action and are thus not targeted by the same inhibitor
molecules [Bieliauskas et al.; 2008; Federico et al., 2011]. Therefore, to establish the role
of deacetylases in regulation of WRN acetylation, we used inhibitors specific to different
classes. TSA specifically inhibits Classes I, II and IV by targeting the zinc molecule
found in the active site of HDACs. Nicotinamide inhibits Class III by binding to the
conserved pocket of sirtuins that participates in NAD+ cofactor binding and catalysis.
First, we treated cells with both inhibitors to hinder deacetylases of the different classes
at the same time and gain knowledge about the dynamics of WRN acetylation. In these
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Figure 2.8 Kinetics of WRN acetylation. A) Cells were incubated in growth medium
with or without 1 mM MMS for 1-4 h before harvest for immunoprecipitation with antiacetylated lysine antibody. The IP products were subjected to SDS-PAGE and Western
blotting with anti-WRN antibody (upper panel). 45 ug of each cell lysate were subjected
to SDS-PAGE and Western blotting with anti-WRN antibody (lower panel) to ensure that
equal amount of total WRN was present in the IP reactions as control. For the recovery
experiments, cells were washed twice with growth medium after 4 h incubation with
MMS and new medium was added to the culture. Cells were harvested after 2 h or 4 h
recovery. Lanes 1 is purified acetylated WRN (upper panel) or purified unmodified WRN
(lower panel) that we used as marker (MKR). B) Quantitative graph for WRN acetylation
and percentages of BrdU incorporation (N.D. signifies non-detectable).
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experiments, cells were treated with MMS alone or with MMS and both inhibitors for 4
h. Interestingly, co-treatment of cells with MMS, TSA and nicotinamide results in a
further increase of WRN acetylation when compared to cells treated with MMS alone
(Figure 2.9A, upper panel, compare lines 3 and 4). We also treated cells with HU alone or
with HU and both inhibitors. Co-treatment with HU, TSA and nicotinamide also resulted
in a further amplification of WRN acetylation levels when compared to cells treated with
HU alone (Figure 2.9B, upper panel, compare lanes 3 and 4). The levels of acetylated
WRN also increased in cells treated with the deacetylase inhibitors alone (Figure 2.9A
and 2.9B, upper panels, lanes 5). Quantitation of data from multiple independent
experiments indicates that treatment with both TSA and nicotinamide results in a 5.0 fold
increase in the levels of WRN acetylation (quantitations showed on Figure 2.9D and E).
These results suggest that WRN is actively deacetylated in vivo and that acetylation of
WRN is a dynamic process that, under normal conditions, is at equilibrium through the
opposing actions of acetyltransferases and deacetylases. At the same time, these results
also confirm that our immunoprecipitation reactions were pulling down only the
acetylated form of WRN, since inhibiting deacetylation specifically increased the levels
of acetylated WRN (Figure 2.9A, B and C, lower panels).
To investigate the influence of the different classes of deacetylases in WRN
acetylation levels cells were treated with each of the inhibitors alone. As seen in Figure
2.9C (compare lanes 2 and 3), TSA alone increased 4.0 fold the levels of acetylated WRN
(quantitation on 2.9F). However, nicotinamide alone increased 2.0 fold the levels of
acetylated WRN (compare lanes 2 and 4). Thus, it seems that members of the classical
HDAC family of deacetylase enzymes contribute more substantially to endogenous WRN
deacetylation, at least under conditions in which DNA is not damaged.
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Figure 2.9 Role of HDACs and sirtuins in regulation of WRN acetylation. A) 8-D
cells were incubated in growth medium with or without 1 mM MMS, 5 mM
Nicotinamide (NIC), and/or 10 uM TSA for 4 h before harvest for IP with anti-acetylated
lysine antibody. IP products were subjected to SDS-PAGE and Western blotting with
anti-WRN antibody (upper panel). 50 ug of each cell lysate were analyzed by Western
blotting with anti-WRN antibody (lower panel). B) 8-D cells were incubated in growth
medium with or without 2 mM HU, 5 mM NIC, and/or 10 uM TSA for 10 h before
harvest for IP with anti-acetylated lysine antibody. IP products were subjected to SDSPAGE and Western blotting with anti-WRN antibody (upper panel). 30 ug of each cell
lysate were analyzed by Western blotting with anti-WRN antibody (lower panel). C) 8-D
cells were incubated in growth medium containing 5 mM NIC and/or 10 uM TSA for 4 h.
D, E and F) Quantitative bar graphs for WRN acetylation (mean ± SEM of 3
independent experiments. * = P < 0.05 when compared with control untreated cells, and
# = P < 0.05 when compared with MMS (in D) or HU (in E) alone.
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DISCUSSION
Previous studies have demonstrated that WRN is subject to post-translational
modification, including phosphorylation, acetylation, and sumoylation. Here, we
specifically investigate WRN acetylation in further depth. In particular, the dynamics of
endogenous WRN acetylation and its relationship to DNA damage were examined. We
found that WRN is acetylated under normal conditions and that acetylation of WRN
significantly increases after treatment with DNA damaging agents (MMS, MMC, and
cisplatin) and the replication inhibitor HU, but not after UV. These results are in
agreement with the relative sensitivity of WS cells to these agents.

WRN is also

acetylated after treatment with the DNA damaging agent etoposide [Li et al., 2008].
Interestingly, the DNA damaging agents that induce WRN acetylation in our studies and
others are known to produce lesions resulting in strong blocks to replication [Jung et al.,
2007; Liu et al., 2003]. Therefore, our data strongly suggest that WRN may be acetylated
in response to blockage of replication.
To establish whether WRN acetylation is actually related to the initial level of DNA
damage or to a downstream effect of the damage on DNA metabolism, it was relevant to
consider if increasing the frequency and persistence of DNA damage induced a further
increase in the levels of acetylated WRN. Thus, we performed a series of experiments in
which DNA damage removal by standard repair pathways was inhibited after treatments
with appropriate DNA damaging agents. Initially, we tested the involvement of O6methylguanine adducts produced by MMS in inducing WRN acetylation by using O6benzylguanine to inactivate MGMT, the enzyme involved in repair of these lesions.
However, our results showed that O6-methylguanine lesions probably do not result in
WRN acetylation, since their apparent persistence does not lead to an increase in WRN
acetylation. To better define if persistence of other lesions produced by MMS results in
amplification of WRN acetylation, we also targeted BER, which is responsible for repair
of 7-methylguanine and 3-methyladenine lesions [Wyatt et al., 2006]. BER was inhibited
with olaparib, which inhibits PARP, the enzyme involved in opening up damaged DNA
to allow access to other components of the repair process. Our experiments demonstrated
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an association between persistence of 7-methylguanine and 3-methyladenine lesions and
WRN acetylation, since we observed a further increase on WRN acetylation when their
repair was inhibited. It might be possible that the increase in WRN acetylation observed
after MMS and olaparib co-treatment could be to an inhibition of deacetylases and/or an
increase in acetylase activity by olaparib. However, our results suggest that this was not
the case, since the cells treated with olaparib alone had comparable amounts of acetylated
WRN as control untreated cells.
There are several possible explanations for the results obtained with the different
inhibitors. First, it is well established that MMS produces 7-methylguanine at much
higher frequency than 3-methyladenine and O6-methylguanine, in order of abundance,
respectively [Lawley et al., 1975; Cloutier et al., 2001; Wyatt et al., 2006; Zhang et al.,
2006; Boysen et al., 2009]. Therefore, it could be difficult to see any changes in WRN
acetylation caused by O6-methylguanine lesions, since the frequency of these lesions is
low after MMS and any change in WRN acetylation status could be undetectable. On the
other hand, MMS and other agents that induce an increase in WRN acetylation levels
produce lesions that result in blockage of replication [Jung et al., 2007; Liu et al., 2003].
Of the lesions formed by MMS, O6-methylguanine disrupts hydrogen bonding with
cytosine, but otherwise does not alter the double helix to any great extent. Therefore, O6methylguanine does not induce replication blockage, instead causing misincorporation
during DNA replication and giving rise to distinctive G-C to A-T point mutations. If
indeed WRN acetylation is related to a response to blockage of replication, O6methylguanine lesions may not induce amplification of WRN acetylation because they do
not block replication. The results obtained after inhibition of repair of 7-methylguanine
and 3-methyladenine lesions agrees with this notion. Several studies suggest that 7methylguanine and 3-methyladenine present a strong block to DNA synthesis.
Methylation at both the N7 and N3 position of purines also destabilizes the N-glycosidic
bond and renders the modified bases more susceptible to being hydrolyzed into abasic
sites known to block DNA synthesis [Wyatt et al., 2006; Johnson et al., 2007; O’Connor
et al., 1988]. In addition, alkylations of the N3 positions of purines, including 3methyladenine, block DNA replication directly by occupying the minor groove of DNA,
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which is normally free of methyl groups [Lindahl et al., 1993]. Thus, based on the
possible relationship between WRN acetylation and blockage of replication, it is tempting
to speculate that we observed a further amplification in WRN acetylation upon
persistence of 7-methylguanine and 3-methyladenine because of increased frequency of
encounters of replication forks with those lesions in the DNA template that, in turn, more
often block DNA replication.
Although we focused primarily on MMS treatment because it elicited the largest
increase in WRN acetylation, we also wanted to know if the induction and/or persistence
of the lesions caused by other agents used in our initial experiments also increased WRN
acetylation. Thus, we also compared the effect of bulky, covalent DNA adducts generated
by cisplatin in cells deficient or proficient for NER, the repair pathway responsible for
removing the majority of lesions induced by cisplatin. The results of those experiments
demonstrated that cisplatin treatment of NER-deficient cells induced a further increase in
the levels of WRN acetylation when compared with normal NER-proficient cells.
Furthermore, the chromosome instability caused by cisplatin treatment (measured using
the micronucleus assay) suggests that cisplatin lesions are likely to cause replication fork
blockage and collapse. These results using strategies to inhibit DNA repair lead to
several conclusions. First, WRN acetylation can be directly correlated with DNA damage
induced by these agents, instead of some non-specific effect of the agent on some other
aspect of cellular metabolism or physiology. Second, the increase in WRN acetylation
response to repair inhibition indicates that is not the induction but the persistence of
damage. Importantly, our data is consistent and extent previous studies showing WRN
acetylation after DNA damage [Blander et al., 2002; Li et al., 2008; Muftuoglu et al.,
2008]. Here, we took a step further and established (for the first time) a relationship
between WRN acetylation and persistence of DNA damage.
In this study, we have demonstrated that WRN acetylation is a dynamic process.
Specifically, we have shown that there is a time-dependent increase of WRN acetylation,
reaching the maximum levels within 4 h after MMS treatement. These results are in
agreement with previous studies showing temporal increase on WRN acetylation levels
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after etoposide treatment [Li et al., 2008]. Interestingly, our flow cytometry analysis after
MMS treatment indicates that the increase in the levels of acetylated WRN correlates to
an increase in the percentage of S-phase cells. In light of these findings, it was relevant to
consider if WRN acetylation has a relationship to DNA replication. Thus, the
incorporation of BrdU was measured after HU and MMS treatments. Interestingly, HU
and MMS treatments markedly decreased the levels of BrdU incorporation. Since WRN
acetylation increased in response to HU and MMS treatments, our results indicate that
WRN acetylation correlates with inhibition of DNA synthesis. Further, our findings
strongly suggest that WRN acetylation observed after DNA damaging agents and
replication blocking agents might arise as a response to DNA damage-induced replication
stress.
Since the acetylation state of WRN is influenced by acetylases and deacetylases, we
inhibited the groups of deacetylases to study their role in regulation of WRN acetylation.
For those experiments, we used the drugs TSA and nicotinamide in order to inhibit
various deacetylases between the different classes of deacetylases that exist in humans.
The result of those experiments revealed that, even in the absence of DNA damaging
treatments, deacetylase inhibitors amplified the levels of WRN acetylation by five fold.
This result indicates that WRN acetylation state is determined by equilibrium between
acetylation and deacetylation. Thus, disruption of this equilibrium, in this case through
the inhibition of deacetylases, results in a shift towards increased WRN acetylation.
These experiments also suggest that another scenario for amplification of WRN
acetylation levels in response to DNA damage might be a change in the balance between
acetylases and deacetylases. Our results suggest that DNA damage shifts the balance
towards acetylation and perhaps increased acetylase or decreased deacetylase activity.
Thus, the status of WRN acetylation might be regulated further by the presence of
specific proteins involved in the acetylation process, which might favor specific
acetylated or deacetylated forms of WRN.
We also studied the role of the different classes of deacetylases in regulation of WRN
acetylation. To date, the classes have been divided into two families and our results
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indicate that members of both families contribute to WRN deacetylation. In our studies,
Class I, II and IV, that are the members of the HDAC family, appear to play a larger role,
since TSA resulted in higher levels of WRN acetylation when compared to nicotinamide
alone. These results indicate, for the first time, that acetylated forms of WRN are
substrates for the Class I, II and IV of histone deacetylase enzymes. However, sirtuins
(Class III) also play some role in regulation of WRN acetylation, since nicotinamide
treatment alone at least doubled the amount of acetylated WRN when compared with
untreated cells. The latter results are in agreement with recent studies showing interaction
and regulation of WRN by sirtuins. Specifically, recent studies have shown that: 1) WRN
interacts with SIRT1 both in vitro and in vivo and is hypoacetylated in cells
overexpressing SIRT1 [Law et al., 2009; Li et al., 2008], 2) sirtuin deacetylase activity
protects WRN from ubiquitination and sequential degradation by the 26S proteosome
[Kahyo et al., 2008, Li et al., 2010], 3) SIRT6 collaborates with WRN at telomeric
chromatin [Michishita et al., 2008], and 4) SIRT1 deacetylation regulates WRN helicase
and exonuclease activity (see Figures 3.2 and 3.3 in Chapter 3). In addition, our results
are consistent with studies showing WRN regulation in response to deacetylase
inhibitors. Specifically, in response to TSA treatment, WRN translocates from the
nucleolus to nucleosplasmic foci, a movement that correlates with WRN acetylation
[Blander et al., 2002; Karmakar et al., 2005]. A recent study identified six lysine residues
(K366, K887, K1117, K1127, K1389, and K1413) that are subject to acetylation on
ectopically expressed, acetylated WRN [Li et al., 2010]. Thus, different deacetylases
might target different acetylated lysine sites on WRN. More research needs to be done to
determine which deacetylases are responsible for removing acetyl groups from individual
lysines.
In summary, we report here that DNA damage and replication blocking agents induce
WRN acetylation. Our results support the view that WRN is acetylated in response to
blockage of replication. Cell cycle analysis, BrdU incorporation assays, and the effect of
persistent DNA damage results are consistent with this possibility. Our findings regarding
WRN regulation by deacetylases show for the first time that deacetylation of endogenous
WRN is influenced by not only sirtuins but also HDACs. Since acetylation of WRN is a
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transient process, we speculate that modification of WRN is used as a rapid way to
respond to cellular stress. Collectively, our study has identified a crucial process by
which WRN is regulated in response to DNA damage and blockage of replication. These
results are in agreement with its putative role in DNA metabolism and maintenance of
genome stability.
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CHAPTER III

WRN ACETYLATION REGULATES ITS ENZYMATIC ACTIVITIES

INTRODUCTION
The amino acid sequence of WRN revealed several functional domains including its
identification as a member of the RecQ family of helicases. To date, several laboratories
have overproduced and purified recombinant wild type and mutant WRN proteins to
characterize their catalytic activities and properties. As expected from its strong
homology to RecQ helicases, WRN’s central region confers ATPase activity that
provides the energy for unwinding DNA with a 3’→5’ directionality [Gray et al., 1997;
Suzuki et al., 1997; Shen et al., 1998; Chen et al., 2002]. Furthermore, the existence of
an N-terminal RNase D-type domain, not present in any other human RecQ member,
confers to WRN an intrinsic 3’→5’ exonuclease activity [Huang et al., 1998; Shen et al.,
1998b; Mian et al., 1997]. Interestingly, the exonuclease and helicase activities of WRN
have been shown to be physically and functionally separable [Huang et al., 1998]. How
these functions are coordinated during DNA metabolism is unknown. However, what is
well-known is that both activities (helicase and exonuclease) of WRN occur
preferentially on complex DNA structures, such as those formed during replication and
recombination, including forks, bubbles, and Holliday junction intermediates
[Constantinou et al., 2000; Brosh et al., 2001; Mohaghegh et al., 2001; Lebel et al., 1999;
Orren et al., 2002; Opresko et al., 2004]. The unwinding activity also disrupts unusual
DNA structures such as G-quartets and triplexes [Brosh et al., 2001; Johnson et al.,
2010]. In addition, WRN possesses DNA binding activity that appears to be dependent
upon DNA structure with no apparent nucleotide sequence preference [Orren et al., 1999;
Brosh et al., 2002]. The affinity of both the helicase and exonuclease for alternative DNA
structures might reflect their roles in resolving specific DNA intermediates that might
form during DNA metabolism.
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Just downstream of the helicase domain there are additional sequences in WRN
typical of some RecQ members, known as the RecQ-conserved (RQC) and the Helicase
and RNase D C-terminal (HRDC) domains. These domains fold into distinct structural
entities and have DNA binding affinities [Liu et al., 1999; von Kobbe et al., 2003; Hu et
al., 2005; Lee et al., 2005]. In fact, experiments using truncated versions of WRN have
shown that it possess four distinct DNA binding regions, including the helicase, RQC and
HRDC domains [von Kobbe et al., 2003]. The exonuclease domain also possesses DNA
binding affinity [Machwe et al., 2006].
WRN deficiency causes replication abnormalities and hypersensitivity to agents that
severely inhibit replication fork progression, suggesting that WRN might participate in
resolution of replication blockage. It has been proposed that the first step in dealing with
a blocked replication fork involves its regression. This process occurs through reannealing of the parental strands and pairing of the daughter strands to generate a
Holliday junction structure or “chicken foot intermediate” [Haber et al., 1999; Cox et al.,
2002]. Fork regression would be facilitated by an enzyme that possesses both unwinding
and strand annealing activity. Interestingly, similar to some recombination proteins,
WRN also facilitates the pairing of complementary DNA strands, this annealing activity
works in concert with its helicase activity to perform strand exchange and regress model
replication forks [Machwe et al., 2005; Machwe et al., 2006]. The latter suggests that
WRN, as part of its role in a genome maintenance pathway, might be involved in the
correct resolution of intermediates that arise from blocked replication forks in vivo,
caused by DNA damage. Thus, the genomic instability of WRN-deficient cells may be
due to an inability to complete normal DNA replication in the absence of functional
WRN.
The enzymatic activities of WRN on DNA substrates have been shown to be
modulated by post-translational modifications [Kusumoto et al., 2007]. Specifically, its
helicase and exonuclease activities are regulated by phosphorylation [Karmakar et al.,
2002; Yannone et al., 2001; Cheng et al., 2003]. Importantly, WRN is subject to posttranslational modifications following DNA damage. These modifications correlate with
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WRN nuclear re-localization to replication foci, a likely site for WRN function in DNA
metabolism [Blander et al., 2002; Cheng et al., 2003; Pichierri et al., 2003; Woods et al.,
2004; Karmakar et al., 2005]. Collectivelly, these studies suggest that it is likely that
cellular WRN trafficking and function is regulated by protein modification, and perhaps
may be related to a specific DNA damage response pathway.
Our studies have demonstrated that genotoxins induce WRN acetylation (see chapter
II). In order to further understand the effect of WRN acetylation on its biochemical
function, unmodified WRN, acetylated WRN and deacetylated WRN protein (expressed
in and purified from HEK293 cells) were compared as to their helicase, exonuclease, and
fork regression activities on relevant DNA structures, with particular emphasis on WRN
action on model replication forks. In this chapter, we report that acetylated WRN has
significantly less exonuclease and helicase activities than unmodified WRN on simple
DNA substrates (partial DNA duplexes). Interestingly, deacetylation of WRN at least
partially restored the normal level of exonuclease and helicase activities. When a more
rigorous examination was done on more complex DNA substrates including replication
forks, surprisingly, the effect of acetylation on WRN fork regression activity was much
less pronounced. Importantly, we provide evidence that the exonuclease activity of
unmodified and acetylated WRN on model replication forks is comparable. Together,
these experiments suggest that WRN acetylation helps to regulate WRN specificity by
reducing its preference for non-physiological substrates.

RESEARCH DESIGN

SPECIFIC AIM: To investigate the effect of WRN acetylation on its biochemical
functions

RATIONALE
Our previous studies demonstrate that WRN is acetylated after treatment of cells with
DNA damaging agents, particularly those that block replication fork progression. It has
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been shown that phosphorylation of WRN after treatment with DNA damaging agents
decreases its exonuclease and helicase activities [Karmakar et al., 2002; Yannone et al.,
2001; Cheng et al., 2003], indicating that WRN modification might alter its catalytic
activities. However, it is unclear if acetylation alters WRN catalytic activities. To this
end, we analyzed in detail how WRN acetylation influences its catalytic activities.
Specifically, unmodified and acetylated WRN were compared as to their helicase,
exonuclease and fork regression activities. Initially, unmodified WRN was directly
compared to acetylated WRN or deacetylated WRN on simple DNA partial duplexes in
regard to their helicase and exonuclease activities. Since WRN has higher specificity for
complex DNA substrates, such as those form during DNA replication and recombination
(including Holliday junction and forks), we also studied the fork regression and
exonuclease activities on model replication forks and Holliday junctions. A mutant WRN
protein containing lysine to arginine mutations at conserved acetylation sites which
cannot be acetylated was analyzed, to determine if indeed WRN acetylation sites are
required for WRN catalytic activities.

METHODS

Production and purification of unmodified and modified wild-type and mutant
FLAG-WRN proteins. FLAG-tagged unmodified, acetylated, deacetylated, and mutant
WRN proteins were overexpressed in HEK293 cells using a transient transfection assay
(performed in the laboratory of our collaborator, Dr. Jianyuan Luo, University of
Maryland Medical School). Unmodified FLAG-WRN and acetylated FLAG-WRN were
expressed and purified as described previously (see methods section in Chapter II). To
produce the FLAG-WRN 6KR mutant, site-directed mutagenesis was used to convert
lysine residues (K366, K887, K1117, K1127, K1389, and K1413) to arginine.
DNA substrate construction. Oligonucleotides were purchased from Integrated DNA
Technologies and their sequences are given in table 3.1. Each substrate was generated by
radiolabeling the 5’ end of one strand (depicted in each figure) with [ɤ-32P] ATP and T4
polynucleotide kinase followed by annealing with a two-fold excess of one or more
52

unlabeled complementary strand(s). Annealed substrates were separated by native PAGE
(12%), excised, and extracted. Labeled oligomers and annealed duplex substrates were
then purified using a gel extraction kit (Qiagen).
The forks were constructed by radiolabeling one oligomer (the specific oligomer used
is depicted in each figure) with [ɤ-32P] ATP and T4 polynucleotide kinase, 3’phosphatase free (Roche Molecular Biologicals, Indianapolis, IN). In an initial annealing
step to form parental daughter partial duplexes, labeled strand was heated to 90°C and
slow-cooled with excess complementary unlabeled daughter strand, while the other
unlabeled parental strand was treated similarly in individual reactions with excess of its
complementary daughter strand. The resulting lagging and leading parental-daughter
partial duplexes were then mixed together at 37°C for 18 h. After separation by native 8%
PAGE, the substrate was excised, extracted into TEN buffer (10mM Tris, pH 8.0, 1 mM
EDTA and 10 mM NaCl), and stored at 4°C prior to use.
Helicase and Fork Regression Assays. To measure enzyme-catalyzed unwinding, the
DNA substrates were incubated without or with unmodified, acetylated and deacetylated
FLAG-WRN proteins (as indicated in figures) in WRN reaction buffer [40 mM Tris-HCl,
pH 8.0, 4 mM MgCl2 (unless otherwise indicated), 1 mM ATP (or 0.25 mM when
indicated), 0.1% Nonidet P-40, 0.1 mg/ml bovine serum albumin (BSA), and 5 mM
dithiothreitol] at 37°C for the specified times. Reactions were subsequently incubated
with Proteinase K (1 mg/ml), SDS (0.2%) and EDTA (5 mM) for 30 min (or 1 h when
indicated) at 37°C and then stopped by addition of one-sixth volume of loading dyes
(30% glycerol, 0.25% bromphenol blue, 0.25% xylene cyanol, and 50 mM EDTA).
Samples were subjected to electrophoresis in an 8% native polyacrylamide gel in 1X Tris
borate-EDTA at 100 V for 3 h at room temperature. The gel was vacuum-dried at 80°C
for 1 h, and radioactive DNA products were visualized by phosphorimaging.
Exonuclease Assays. Exonuclease reactions (10 µl) containing the substrate of interest
and FLAG-WRN proteins (at the indicated concentrations) in WRN reaction buffer
without, or with 1 mM ATP (when indicated in figures), were preincubated on ice for 5
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min, and then transferred to 37°C for the indicated times. Reactions were stopped by the
addition of formamide loading buffer (95% formamide, 20 mM EDTA, 0.1% bromphenol
blue, and 0.1% xylene cyanol). DNA products were heated at 90°C and separated by
denaturing (14%) PAGE. Digestion of the labeled strand by the 3’ to 5’ exonuclease
activity of WRN proteins was visualized by phosphorimaging.

RESULTS
Acetylation alters WRN biochemical activities and specificity. Our results
demonstrated that WRN is acetylated in response to DNA damaging agents and
replication blocking agents. To further understand the function of WRN in DNA
metabolism, we analyzed in detail how WRN acetylation influences its catalytic
activities. Using the protocol depicted in Figure 3.1A, unmodified FLAG-WRN,
acetylated FLAG-WRN and deacetylated FLAG-WRN were made from HEK293 cells.
Western blot techniques were used to determine their protein levels and confirm the
acetylated state (Figure 3.1B). First, these proteins were used to perform a helicase assay
on a 21-bp partial duplex with a 49-nt 3’ overhang structure constructed by annealing
oligomers 21-lag and 70-lag. (Figure 3.2A, for details; see “Methods” section and Table
3.1 for nucleotide sequences). We started out using this kind of substrate, with one blunt
end and the other end with a 3’ single-stranded region, because the helicase activity of
WRN requires a 3’ single-stranded DNA region relative to the duplex DNA to be
unwound. Using equivalent protein concentrations, acetylated FLAG-WRN showed
significantly less helicase activity than FLAG-WRN (Figure 3.2B, lanes 5-7 vs. lanes 24). Interestingly, deacetylation of WRN almost completely restored the normal level of
helicase activity (Figure 3.2B, lanes 8-10 vs. lanes 5-7). A quantitative graph for WRN
unwinding activity is presented in Figure 3.2C. Thus, acetylation appears to suppress
WRN helicase activity on simple partial duplexes.
Using the same proteins, exonuclease assays were performed on different partial
duplex substrates with a recessed 3’-end structure (see structures in Figure 3.3), to
determine the effect of acetylation on WRN exonuclease activity. These substrates with
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Figure 3.1 WRN acetylation assay. A) To obtain unmodified FLAG-WRN, cells were
transfected with vector specifying production of FLAG-WRN. To obtain acetylated
WRN, cells were co-transfected with individual vectors specifying production of FLAGWRN and CMV-p300 or CMV-CBP (two acetyltransferases that acetylate WRN in vivo
[Li et al., 2010]). To obtain deacetylated FLAG-WRN, cells were co-transfected with
FLAG-WRN, CBP (since it is the major acetylase involved in WRN acetylayion [Li et
al., 2010]) and SIRT1 (a histone deacetylase) vectors. Cells were harvested 36 h after
transfection and were lysed in a FLAG-lysis buffer. After anti-FLAG M2
immunoprecipitation, the immobilized FLAG-WRN proteins were released using FLAG
peptide and purified unmodified or acetylated FLAG-WRN was collected. To confirm
that the system works and determine protein concentration and the level of acetylation,
the purified FLAG-WRN proteins were resolved by SDS-PAGE and detected by western
blot. B) For each transfection strategy, WRN was produced (lower panel). In the case of
cotransfection with p300 or CBP, acetylated WRN was produced (upper panel, lane 2),
and in the case of cotransfection with p300 and SIRT1, the levels of acetylated WRN
were dramatically reduced (upper panel, lane 3).
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Table 3.1
Oligonucleotides used to construct DNA substrates
_______________________________________________________________________________
21-lag
GAGGATATCATGTACGATAGCP
21- lead
GCTATCGTACATGATATCCTCP
K21RP3
TAGGGTTAACATCAAGTCACGP
30-lead
GCTATCGTACATGATATCCTCACACTCACT
32-lag
ATTCAGAGTGTGAGGATATCATGTACGATAGCP
G35left
AGCTCCTAGGGTTACAAGCTTCACTAGGGTTGTCC
3(52)scr
CACTCCTCTGAGTCTGGACGGCAGCTGGCCAAGTGTGAGTGTGAGTGTGAGT
5’(52)
TCACTTGACAAGTGACTGTGACCTAGGCATCCTCCAGTTCCTGGAGTCAGTG
70-lag
GCTATCGTACATGATATCCTCACACTCTGAATAGCCGAATTCTTAGGGTTAGGGTTAACATCAAGTCACGP
70 lead
CGTGACTTGATGTTAACCCTAACCCTAAGAATTCGGCTTAAGTGAGTGTGAGGATATCATGTACGATAGC
K70P3
CGTGACTTGATGTTAACCCTAACCCTAAGAATTCGGCTTAAGTGAGTGTGAGGATATCATGTACGATAGCP
K70left fork
CAGCAACATACATTGTAAGAGCATACAGACACGCACGAATTCTTAGGGTTAGGGTTAACATCAAGTCACGP
K70right fork
GCTATCGTACATGATATCCTCACACTCACTTAAGCACTCAGGCACTCTAGCTCTGCTCACGACCAGACATP
C80
GCTGATCAACCCTACATGTGTAGGTAACCCTAACCCTAACCCTAAGGACAACCCTAGTGAAGCTTGTAACCCTAGGAGC
TP
*base
CACTGACTCCAGGAACTGGAGGATGCCTAGGTGGCCAGCTGCCGTCCAGACTCAGAGGAGTG
HJ70M8-1
GCTATCGTACATGATATCCTCACACTCACTTAAGCCGAAGAGAATCCTGATCTCAATTGTAGTTCAGTGCP
HJ70M8-2
GCACTGAACTACAATTGAGATCAGGATTCTCTTCGGCTTCTCATTCACACTCCTATAGTACATGCTATCGP
HJ70M8-3
CGATAGCATGTACTATAGGAGTGTGAATGAGAAGCCGAATTCTTAGGGTTAGGGTTAACATCAAGTCACGP

All sequences are depicted in 5’ to 3’ orientation
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Figure 3.2 WRN helicase activity is regulated by acetylation. A) Substrate containing
the 3’ overhang constructed by annealing oligomers 21-lag and 70-lag. The relative
position and size of the complementary region (21 bp) is indicated. B) Helicase assay was
performed with 21-bp partial duplex using FLAG-WRN, acetylated FLAG-WRN, and
deacetylated FLAG-WRN produced as explained in figure 3.1. The 3’ overhang (5 fM)
was incubated at 37°C for 10 min with FLAG-WRN proteins (80, 160, and 320 pM) and
analyzed as described in the Methods section. C) Graphic representation for WRN
unwinding activity (mean and S.D. for three independent experiments).
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one blunt end and the other end with a recessed 3’ end were selected for our initial
studies because they are resistant to the helicase activity of WRN (the helicase activity
requires a 3’ single-stranded region). Therefore, when WRN is added to these substrates,
the exonuclease activity is directed to the recessed end (Figure 3.3A). Exonuclease
activity at the 3’ end of the labeled strand is measured by the appearance of shorter
fragments on a denaturing gel. As expected, WRN degrades the 3’-end of the labeled
strand in a step wise manner in a 3’ to 5’ direction (Figure 3.3B, lines 2-4). Interestingly,
acetylation of WRN markedly decreased its exonuclease activity (Figure 3.3B, lanes 5-7
vs. lanes 2-4). Again, deacetylation of WRN can reverse this effect (Figure 3.3B,
compare lanes 8-10 vs. lanes 5-7). An eight fold molar excess of acetylated WRN is
needed to obtain similar exonuclease activities between unmodified and acetylated WRN
on this recessed 3’ end substrate (Figure 3.3C, compare lines 2-4 to 5-7). Although an
ATP requirement is connected with unwinding and the exonuclease activity of WRN is
not ATP-dependent, several laboratories have shown that WRN exonuclease activity is
stimulated by ATP hydrolysis on certain substrates [Kamath-Loeb et al., 1998; Machwe
et al., 2002; Shen et al., 2000; Brosh et al., 2001]. Thus, we added ATP to the
exonuclease reactions to investigate if ATP can stimulate the exonuclease activity of
acetylated WRN. However, the exonuclease activity of acetylated WRN was not
significantly stimulated even in the presence of ATP (Figure 3.3D, lane 2 vs. 3).
Collectively, these results indicate that acetylation decreases WRN exonuclease activity
on simple partial duplex substrates.
It is well known that WRN prefers special DNA structures, such as those formed
during replication and recombination, including forks [Opresko et al., 2003].
Importantly, WRN coordinates its annealing activity with its helicase activity to perform
strand exchange and regress model replication forks [Machwe et al., 2005; Machwe et al.,
2006]. The latter support the notion that WRN might be involved in the correct resolution
of intermediates that arise from blocked replication forks in vivo, caused by DNA
damage. Therefore, we wanted to explore the effect of WRN acetylation on more
complex structures. To this end, a more rigorous examination was done by comparing the
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Figure 3.3 WRN exonuclease activity is regulated by acetylation. A) WRN
exonuclease directionality is defined as 3’ to 5’ with respect to the direction that the
single strand of the DNA substrate is degraded, as despicted in the figure. Exonuclease
activity at the 3’ end of the labeled strand is measured by the appearance of shorter
fragments on a denaturing gel. B) Time course of the exonuclease activities of FLAGWRN proteins on a 35-bp partial duplex with a recessed 3’ end probe (0.1 nM),
constructed by annealing oligomers G35left and C80, at 37°C were compared. C) The
time course exonuclease activities of unmodified FLAG-WRN and 8-fold molar excess
of acetylated FLAG-WRN protein on a 3’-end probe (0.1 nM) constructed by annealing
oligomers 30-lead and K70P3. D) Reactions containing 3’ end probe (0.1 nM)
constructed by annealing oligomers 30-lead and K70P3 with or without ATP (1 mM), as
indicated, were incubated at 37°C for 15 min.
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unwinding strength and fork regression activities of unmodified and acetylated WRN on
a series of DNA substrates constructed using the same labeled strand. Briefly, a labeled
80-nt strand was annealed with different unlabeled complementary strands to produce a
3’ overhang structure, a 2-stranded fork, a 3-way junction and a model 4-stranded
replication fork as well as a Holliday junction structure (see structures in Figure 3.4A and
3.5A) that were subsequently purified. The common labeled strand made it
straightforward to use precisely the same molar amounts of these DNA substrates to
facilitate direct comparison in enzymatic assays. For these assays, these substrates were
incubated in WRN-reaction buffer containing unmodified or acetylated WRN. As shown
in figure 3.4A and B, unmodified WRN unwinds the 2-stranded fork (compare lines 5
and 6) and the 3-way junction (compare lines 8 and 9) with higher efficiency than
acetylated WRN, in order of preference, respectively. As expected, the 3-way junction
was unwound to a variety of products that were included in the calculation. We further
tested a series of 3-way junction with different sequences on the 3’-flap and, consistent
with these results, acetylated WRN was less efficient than unmodified WRN (data not
shown). The difference between unmodified and acetylated WRN unwinding activities
was less dramatic on the 3’ overhang substrate (compare lines 2 and 3). Unwinding of the
Holliday junction substrate was not detected (data not shown), likely because of the
length of the duplex regions of this substrate. In contrast, unmodified and acetylated
WRN have comparable fork regression activity (Figure 3.4A, compare lines 11 and 12).
In parallel, we measured the exonuclease activities of unmodified and acetylated WRN
on the same substrates. Similar to previous results, the exonuclease activity of
unmodified WRN was stronger than the exonuclease activity of acetylated WRN on the
3’ overhang (Figure 3.5A, compare lines 2 and 3) and the 2-stranded fork (compare lines
5 and 6). However, the exonuclease activities of unmodified and acetylated FLAG-WRN
were comparable on the 3-way junction (compare lines 8 and 9) and the model replication
fork (compare lines 14 and 15). On the Holliday junction (compare lines 11 and 12),
unmodified WRN appeared to be slightly mor active than acetylated WRN. A
quantitative chart for WRN exonuclease activity on the different substrates is presented in
Figure 3.5B. Taken together, these results suggest that acetylation of WRN alters its
specificity for certain types of substrates.
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Figure 3.4 Acetylation regulates WRN specificity. A) A labeled 80-nt strand (K70P3
oligomer) was annealed with different unlabeled complementary strands to produce a 3’
overhang structure (K21RP3 oligomer + K70P3 oligomer), a 2-stranded fork (K70left
fork oligomer + K70P3 oligomer), and a 3-way junction (K70left fork oligomer +
K70right fork oligomer + K70P3 oligomer). The model replication fork was generated
by annealing parental daughter partial duplexes (labeled K70P3 + unlabeled 21-lead
oligomer and unlabeled 70-lag + excess 32-lag oligomer). After individual substrates
were gel-purified, these substrates (0.1 fm) were incubated at 37°C for 1 h in WRNreaction buffer containing unmodified or acetylated WRN and analyzed as described in
the Methods section. B) For experiment in A, percent of unwinding/regression was
calculated (mean and S.D. for four independent experiments).
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Figure 3.5 Acetylation regulates the specificity of WRN exonuclease activity. A) The
substrates constructed using the same labeled 80-nt strand (as described in Figure 3.5A)
were incubated at 37°C for 1 h in WRN-reaction buffer containing unmodified or
acetylated WRN and analyzed as described in the Methods section. The Holliday junction
was constructed by annealing of the labeled K70P3 oligomer with unlabeled partial
complementary strands (HJ70M8-1 oligomer + HJ70M8-2 oligomer + HJ70M8-3
oligomer). B) For experiment in A, percent reduction of full length labeled strand by
WRN exonuclease activity was calculated.
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To confirm that unmodified and acetylated WRN have comparable fork regression
activities, a different model replication fork was designed (see Figure 3.6A for details)
and the fork regression activities of unmodified WRN and acetylated WRN were
compared over a range of concentrations. Again, the difference in fork regression activity
was much less pronounced, as manifested specifically by daughter duplex formation that
is a diagnostic of fork regression (Figure 3.6B, lines 2-4 vs. 5-7). However, they have
minor differences in the generation of other products that result from the helicase and
exonuclease activities of WRN. After these interesting results we analyzed the
exonluclease activity of WRN on this substrate. Interestingly, unmodified and acetylated
WRN showed similar efficiency in exonuclease degradation of the labeled strand of this
fork substrate (Figure 3.6C, lanes 2-4 vs. 5-7). Together, these results suggest that
unmodified and acetylated WRN have comparable activities on four-stranded replication
forks.
Recently, lysine residues subject to acetylation were identified after performing a
mass spectrometry analysis of purified ectopically expressed acetylated WRN (obtained
after co-transfection of FLAG-WRN with the acetylases CBP and p300 in HEK293 cells)
[Li et al., 2010]. According to that study, the acetylated lysine residues in WRN are
K366, K887, K1117, K1127, K1389, and K1413. Thus, as a negative control, we studied
a WRN mutant containing all six lysines mutated to arginine, a conservative basic amino
acid substitutions that cannot be acetylated, to examine whether any of these residues are
required for WRN enzymatic function. In these experiments, the helicase and
exonuclease activities of unmodified FLAG-WRN and the 6KR mutant were compared
on simple partial duplexes substrates. To amplify the inherent exonuclease activity of
WRN, certain reactions were carried out using Mn2+ instead of Mg2+ as a co-factor. As
shown in Figure 3.7A and B, the WRN 6KR mutant maintains similar activities as the
wild type (unmodified) WRN under the conditions used, suggesting that the arginine
substitutions do not directly affect WRN enzymatic properties or the folding of the
protein.
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Figure 3.6 Effects of WRN acetylation on a model replication fork. A) A model
replication fork was constructed containing homologous leading and lagging arms with
five nucleotides of heterology at the fork junction to prevent spontaneous branch
migration. Regression the fork is determined specifically by daughter duplex formation
which requires unwinding and pairing of the physically unlinked daughter strands. B)
Equal and increasing amounts of unmodified and acetylated WRN were assayed for fork
regression activity on the replication fork model (4 pM) and analyzed as described in the
Methods section. C) Exonuclease activities of unmodified and acetylated FLAG-WRN
proteins on the model replication fork over 30 min at 37°C in WRN reaction buffer
(including 1 mM ATP). DNA products were separated by denaturing (14%) PAGE and
visualized by phosphorimaging.
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Figure 3.7 WRN 6KR-mutant retains similar activities as the WRN-wt. A) Helicase
assay was performed with a partial duplex, containing a 31 and 21 nt 5’ and 3’ singlestranded arms (constructed by annealing oligomers 3(52)scr and *base), using FLAGWRN (WRN-wt) and the FLAG-6KR-mutant (WRN 6KR) produced as explained in the
Methods section. The partial duplex was incubated at 37°C for 30 min with FLAG-WRN
proteins in WRN reaction buffer (including 1 mM MgCl2 or 1 mM MnCl2, as depicted,
and 0.25 mM ATP) and analyzed by native PAGE. B) Exonuclease activities of
unmodified and 6KR-mutant FLAG-WRN proteins on a partial duplex (constructed by
annealing oligomers 5’ (52) and *base) over 20 min at 37°C in WRN reaction buffer
(including 1 mM MnCl2 instead of MgCl2 when indicated).

DNA products were

separated by denaturing (8%) PAGE and visualized by phosphorimaging.
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DISCUSSION
The genomic instability and hypersensitivity to DNA damaging agents of WS cells are
thought to be caused by DNA metabolic defects that result from absence of WRN
function. This notion has been supported by the identification of 3’→ 5’ helicase and
3’→ 5’ exonuclease activities of WRN. Notably, WRN has been reported to possess
strand annealing and strand exchange activities. Most recently, this notion has been
strengthened by the discovery of a new activity in WRN, when Machwe et al. reported
that WRN regresses model replication forks [Machwe et al., 2006]. Collectively, these
biochemical properties of WRN suggest that it has an important role in DNA metabolism.
Interestingly, the enzymatic activities of WRN on DNA substrates have been shown to be
modulated by phosphorylation [Karmakar et al., 2002; Yannone et al., 2001; Cheng et al.,
2003]. However, how WRN activities are regulated by acetylation remain to be
elucidated. In this study, we report the impact of acetylation on WRN catalytic activities
using helicase, exonuclease, and fork regression assays.
Initially, WRN helicase and exonuclease activities of unmodified and acetylated WRN
were compared using simple DNA partial duplexes structures. Our experiments clearly
demonstrate that acetylated WRN has markedly less helicase and exonuclease activities
than unmodified WRN indicating that WRN acetylation reduces both helicase and
exonuclease activities, at least on those simple substrates. Deacetylation of WRN could
reverse this effect. However, it is believed that WRN physiological substrates are those
formed during replication and recombination, including forks, since WRN has highest
preference for those kinds of structures and possesses replication fork regression activity.
Thus, a more depth analysis on various DNA structures, including replication forks, was
done. For a 2-stranded fork and a 3-way junction substrate, the unwinding activity of
unmodified WRN was substantially higher when compared with acetylated WRN. The
difference in unwinding activities was less dramatic in the 3’ overhang substrate.
However, the results of experiments performed using a replication fork showed
approximately equivalent fork regression activities between both unmodified and
acetylated WRN. Notably, the exonuclease activity on replication forks between
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unmodified and acetylated WRN was also very similar. Collectively, our data strongly
suggest that WRN acetylation helps to regulate WRN specificity for certain types of
substrates.
Our studies here suggest that the effect of acetylation on WRN enzymatic function is
DNA structure-dependent, with little or no effect on either regression or exonuclease
activity on four-stranded replication forks. Since our previous studies demonstrated that
WRN is acetylated in response to DNA damage and blockage of replication (see Chapter
II), we speculate that WRN acetylation plays an important role in regulation of WRN
function to resolve replication blockage. Specifically, acetylation may reduce WRN
affinity for inappropriate DNA structures, while maintaining specificity for replication
fork structures that are the putative physiological targets for WRN action. In support of a
fundamental role of WRN during DNA replication, replication forks have been shown to
be preferential targets for WRN function, since WRN acts more efficiently on forked
DNA than double-stranded duplex DNA [Brosh et al., 2002; Compton et al., 2008] and
regresses model replication forks in vitro [Machwe at al., 2006 and 2007], an important
process to gain access to the replication-blocking lesion, allowing processive replication
to resume once the blocking lesion is removed. The hypersensitity to replication blocking
agents, prolonged S-phase and reduced lifespan observed in WRN-deficient cell lines are
consistent with our notion as well.
Li and colleagues identified six lysine residues subject to acetylation on WRN [Li et
al., 2010]. Moreover, they demonstrated that WRN acetylation was at the lowest level
detected when all of the six lysines are mutated to arginines, by comparison with single,
double, triple, and quadruple mutants, suggesting that all six lysines are involved in WRN
acetylation. As part of this study, we analyzed if those six lysine residues are required for
WRN enzymatic function. The results of our experiments revealed that these specific
lysines are not required for WRN unwinding and exonuclease activities, indicating that
these residues do not appear to be involved in catalysis and/or protein folding. The fact
that arginine substitutions do not alter WRN’s catalytic activities on simple DNA partial
duplexes structures contrasts with the effect on these activities when WRN is acetylated
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on those lysine residues. Arginine residues cannot be acetylated but retain the positive
charge, as for lysine residues. The positive charges of these amino acids are often
involved in helping mediate binding to the negatively charged backbone of DNA.
Acetylation of lysine eliminates this charge and therefore may alter DNA binding
strength or specificity. Thus, our experiments suggest that acetylation of lysine residues
on WRN might alter DNA binding affinity and enzymatic activities in such a way to
lower the affinity for non-target DNA structures in favor of more physiological
structures. It will be important to address in future experiments whether the relevance of
individual lysine residues for DNA structure selectivity is altered by acetylation.
Addressing these issues should also help to understand how WRN interacts with different
DNA structures.
In summary, we have demonstrated that WRN acetylation helps to regulate WRN
specificity for certain types of substrates, suggesting that WRN acetylation may increase
specificity by reducing preference for non-physiological substrates. Importantly, our
findings have identified that acetylation is likely involved in regulation of the DNA
metabolic function of WRN.

Copyright © Enerlyn Meliza Lozada Santiago 2011
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CHAPTER IV

WRN INTERACTION WITH RPA IN RESPONSE TO AGENTS THAT BLOCK
REPLICATION

INTRODUCTION

Existing evidence suggests an association of WRN with the process of DNA
replication. Specifically, WS cells have dramatically reduced replicative capacity leading
to very early cellular senescence; they grow slowly and have been reported to have a
longer S phase and replication initiation and elongation abnormalities [Martin et al.,
1970; Takeuchi et al., 1982b; Salk et al., 1985; Poot et al., 1992; Yan et al., 1998]. In
addition, WS cells are hypersensitive to DNA damaging agents that tend to block
progression of replication forks such as interstrand crosslinking agents including
mitomycin C and cisplatin, topoisomerase inhibitors such as camptothecin, and DNA
replication inhibitors including HU [Gebhart et al., 1988; Ogburn et al., 1997; Poot et al.,
1999, 2001; Pichierri et al., 2001]. However, sensitivity of WS cells to DNA damaging
agents does not appear to reflect a direct role in an established DNA repair pathway.
Instead, sensitivity to both DNA damaging agents and HU suggests that WRN plays a
role in responding to replication blockage by lesions or other obstructions.

A role for WRN in DNA replication likely involves key physical and functional
interactions with other proteins involved directly or indirectly in completing duplication
of the genome. In support of this notion, it has been reported that WRN associates or
interacts directly with factors involved in DNA replication such as PCNA (which
functions as a clamp to improve DNA polymerase processivity), FEN-1 (which processes
the 5’ ends of Okazaki fragments in lagging strand DNA synthesis) [Lebel et al., 1999;
Brosh et al., 2001b and 2002b; Rodriguez-Lopez et al., 2003; Sharma et al., 2005 ], and
Topo I (which relaxes superhelical tension generated during DNA replication) [Lebel et
al., 1999; Lane et al., 2003]. In addition, WRN interacts with DNA polymerase δ
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[Kamath-Loeb et al., 2000 and 2001; Szekely et al., 2000], a major replicative DNA
polymerase, and with RPA [Shen et al., 1998a and 2003, Brosh et al., 1999, Doherty et
al., 2005, Sommers et al., 2005], a protein heterotrimer that protects single-stranded DNA
and binds to gaps at blocked replication forks. Taken together, these observations suggest
that loss of these interactions in WRN-deficient cells might disrupt key replicationrelated pathways. Specifically, it has been suggested that WRN is involved either in
preventing the collapse of stalled replication forks, or in the resolution of intermediates
present at blocked forks. Consistent with this idea, recent studies have shown that: 1)
WRN expression is upregulated during S and G2 phases in highly proliferative
transformed cell lines [Kawabe et al., 2000b], 2) upon replication arrest, WRN is
redistributed to distinct nuclear foci (associated with ongoing and/or blocked DNA
synthesis) and is modified [Constantinou et al., 2000; Sakamoto et al., 2001], 3) WS cells
have defective elongation showing marked asymmetry of replication forks from
individual bidirectional origins [ Rodriguez-Lopez et al., 2002], and 4) WRN can
coordinate its unwinding and pairing activities to regress a model replication fork
substrate [Machwe et al., 2006]. Thus, the nature of genomic instability, increased cancer
and premature aging observed in WS may be the result of improper resolution of blocked
replication and illegitimate recombination caused by loss of WRN.

RPA is a single-stranded DNA binding protein complex composed of three structural
subunits, RPA70, RPA32, and RPA14, that is involved in DNA replication, repair, and
recombination [Iftode et al., 1999; Wold et al., 1997]. It has been shown that RPA binds
to single-stranded gaps generated by stalled replication forks, helping to protect these
regions and leading to the initiation of downstream pathways [Raderschall et al., 1999;
Wold et al., 1997]. The initiation of those pathways requires the recruitment and
activation of proteins such as ATR/ATRIP, RAD17 complexes, and RAD51 [Dart et al.,
2004; Zou et al., 2003a and 2003b; Binz et al., 2004; Jackson et al., 2002; Golub et al.,
1998], which are critical players for the DNA damage response. Importantly, DNA
damage induces hyperphosphorylation (≥5 residues) of the N-terminal region of the 32
kDa subunit of RPA [Binz et al., 2004; Din et al., 1990; Dutta et al., 1992; Mitsis et al.,
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1995,; Oakley et al., 2001; Shao et al., 1999], presumably to regulate its function in DNA
metabolism.

Several studies have shown that purified recombinant RPA and WRN interact with
each other and that RPA can stimulate WRN unwinding strength in vitro [Brosh et al.,
1999; Shen et al., 1998; Doherty et al., 2005], and it has been suggested that an
interaction between WRN and RPA might occur in vivo within cells. Importantly, RPA
colocalizes with WRN in nuclear foci after treatments that induce blockage of replication
such as HU [Constantinou et al., 2000; Sakamoto et al., 2001; Ammazzalorso et al.,
2010]. Together, this evidence suggests that RPA and WRN might functionally interact at
stalled replication forks. Thus, we were interested to examine the intracellular interaction
between WRN and RPA, particularly in response to blockage of replication. Whether
WRN-RPA association occurs via a direct stable interaction was also analyzed. The
results of these experiments indicate that WRN and RPA form a direct association under
normal physiological conditions in vivo and treatments that block replication fork
progression result in an increased association between them. Thus, our findings further
support the idea that WRN and RPA are involved in DNA replication by working in a
complex at blocked or stalled replication forks.

RESEARCH DESIGN

SPECIFIC AIM: To study if genotoxins influence WRN interaction with RPA
Aim a. To investigate if DNA damaging treatments (known as blockers of
replication) regulate the intracellular interaction between WRN and RPA
Aim b. To analyze whether WRN and RPA association occurs via a direct
interaction
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RATIONALE

The evidence of replication problems in WS cells and the sensitivity of these cells to
inhibitors of replication suggest a direct physical and functional association of WRN with
the process of DNA replication. To play such a role WRN must be located at forks or
recruited to them when needed.

Consistent with this idea, WRN is subject to

translocation from nucleolus to discrete sites, called nuclear foci, in response to DNA
damage and replication blockers. These discrete subnuclear regions are considered as
sites of DNA damage and blocked replication and therefore their formation is an
important stage in DNA metabolism [Nelms et al., 1998].

Interestingly, WRN co-

localizes with RPA in these nuclear foci in response to treatment with the replication
inhibitor HU [Constantinou et al., 2000]. Taken together, these facts support the notion of
an association between WRN and RPA at blocked replication forks. Thus, based on
previous evidence showing in vitro interaction between WRN and RPA, we hypothesized
in this study that these factors interact directly within cells, particularly in response to
replication blockers. Up to this point, an in vivo interaction between WRN and RPA had
not been demonstrated. Therefore, we wanted to address if indeed an intracellular
interaction between WRN and RPA exists in vivo, perhaps specifically in response to
replication fork blockage. If this hypothesis is true, blockage of replication by DNA
damage should induce or increase WRN-RPA association. First, we used coimmunoprecipitation experiments to investigate if WRN and RPA associate within cells
(Aim a). For these experiments, we treated cells with MMS and HU, agents known to
induce blockage of replication, and studied their effect in the association between WRN
and RPA. Then, we analyzed if WRN-RPA association occurs thru a direct proteinprotein interaction (Aim b).

Aim a. To investigate if DNA damaging treatments (known as blockers of
replication) regulate the intracellular interaction between WRN and RPA. The first
specific question we wanted to address in regard to WRN and RPA interaction was: Do
WRN and RPA interact within cells? First, co-immunoprecipitation experiments were
used to examine possible association between WRN and RPA. The second question we
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wanted to address was: Do DNA damaging treatments (that block replication fork
progression) alter the nature of WRN interaction with RPA? For these experiments, we
chose the DNA alkylating agent methylmethanesulfonate (MMS), which methylates the
DNA bases, producing 7-methylguanine, 3-methyladenine and O6-methylguanine [Wyatt
et al., 2006]. Importantly, WRN-deficient cells are hypersensitive to MMS and it induces
specific lesions (7-methylguanine and 3-methyladenine) that physically block replication
fork elongation in cells [Imamura et al., 2002; Harrigan et al., 2006, Groth et al., 2010].
Additionally, we used the replication inhibitor HU, which depletes deoxyribonucleotide
pools by inhibition of the enzyme ribonucleotide reductase, theoretically blocking
progression of all replication forks [Skog et al., 1992, Pichierri et al., 2001]. As for MMS,
WS cells are hypersensitive to HU, most likely by apoptosis of cells with stalled
replication forks [Pichierri et al., 2001]. Thus, we used MMS and HU treatments to
determine if DNA damaging treatments that block replication influence the interaction
between WRN and RPA.

Aim b. To analyze whether WRN and RPA association occurs via a direct
interaction. Although a co-immunoprecipitation experiment from cells might indicate an
association between two proteins, it does not prove a direct interaction between them.
Within a protein complex, proteins might interact directly or indirectly via one or more
bridging molecules, such as other proteins or nucleic acids (DNA or RNA). Thus, we
wanted to analyze whether WRN and RPA association occurs via a direct interaction.
Therefore, we tested whether purified WRN and RPA could directly bind to each other
by Far Western analysis.

METHODS

WRN-RPA Co-immunoprecipitation Experiments. A co-immunoprecipitation assay is
used to target a known protein that is believed to be a member of a larger complex of
proteins (using an antibody specific for the known protein) to pull the entire protein
complex out of solution and thereby identify other members of the complex. For our IP
experiments, we used an SV40-transformed fibroblast cell line, 1-O, that was obtained
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from J. Christopher States, University of Louisville [States et al., 1993].
Methylmethanesulfonate (MMS), phenylmethylsulfonylfluoride (PMSF), HU, and
protease inhibitor cocktail were purchased from Sigma-Aldrich, and cell culture media
and reagents were purchased from Invitrogen. Cells were grown in MEM-α Glutamax
medium supplemented with 10% FBS, 1% HEPES, and 1% penicillin-streptomycin at
37°C in a humidified atmosphere containing 5% CO2. For DNA damaging treatments,
cells were incubated in medium containing 1 mM MMS for 4 h or 2 mM HU for 10 h
before harvesting. For co-immunoprecipitation experiments, cells were lysed by
sonication in RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.25%
sodium deoxycholate, and 1 mM EDTA) supplemented with protease inhibitor cocktail, 1
mM PMSF and 10 units/ml of DNase I (New England Biolabs). After centrifugation at
21,000  g for 12 min at 4°C, supernatants were isolated and their protein concentrations
measured. Samples (800 g of protein each) were pre-cleared with Protein G Plus/Protein
A agarose beads (Calbiochem) and 1 g of normal mouse IgG (Santa Cruz) for 30 min,
then incubated with mouse monoclonal anti-RPA32 antibody (Calbiochem) for 15 h at
4°C. The samples were subsequently mixed with 30 μl of Protein G Plus/Protein A bead
suspension at 4°C for 3 h. After collection by centrifugation and removal of supernatant,
the beads were then washed three times with RIPA buffer supplemented with protease
cocktail inhibitors, 1 mM PMSF and 200 g/ml ethidium bromide. After the final wash,
equal portions of RIPA and 2X SDS sample buffer were added to the beads and
immunoprecipitated proteins were released by heating at 95°C for 5 min. Equal volumes
of each sample were resolved by SDS-PAGE (6% or 12% for WRN or RPA,
respectively).

Proteins

were

transferred

to

PVDF

membranes

(Bio-Rad)

by

electroblotting. The membranes were blocked with 5% nonfat dry milk in TBST buffer
(20 mM Tris, pH 7.4, 140 mM NaCl and 0.1% Tween-20) and analyzed by Western
analysis with rabbit anti-WRN (Santa Cruz) or mouse anti-RPA32 (Calbiochem)
antibodies for 18 h at 4°C followed by chemiluminescent detection using ECL Plus (GE
Healthcare).

Far Western assays. Far Western blot analysis is a method used to study protein-protein
interactions using an immobilized protein on a membrane to capture potential binding
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partners that are then detected on the membrane using specific antibodies. Purified RPA
(60 and 120 ng or 0.5 and 1 pmol, respectively) or recombinant WRN (30, 60 and 90 ng
or 180, 360, and 540 fmol, respectively) and corresponding concentrations of bovine
serum albumin (BSA) were spotted directly onto nitrocellulose membranes. After
allowing the applied samples to dry for 15 min at 4°C, membranes were blocked for 1 h
at 4°C with 5% nonfat dry milk in TBST. The membranes were then incubated in 5 ml of
TBST-5% milk solution (including 25 mM NaCl or 100 mM NaCl as indicated)
containing purified WRN (400 ng = 2.4 pmol) or RPA (360 ng = 3 pmol) for 3 h at 4°C.
After washing three times for 10 min each with TBST, membranes were subjected to
immunodetection by 1) incubation for 1 h with anti-WRN or anti-RPA32 antibody, 2)
incubation

for

1

h

with

appropriate

HRP-linked

secondary

antibodies,

3)

chemiluminescent development using ECL Plus (GE Healthcare) and 4) visualization by
autoradiography. Films were scanned to assess the level of protein binding, with
comparison to RPA standards spotted separately on the same membranes.

RESULTS

Blockers of replication enhance intracellular association of WRN with RPA.
WRN has an important role in the maintenance of genomic integrity [Sidorova et al.,
2008], and accumulating evidence suggests its involvement in a DNA metabolic pathway
that allows the cell to responds to replication blockage to maintain chromosomal stability.
RPA participates in DNA replication and one of its roles is to bind and protect ssDNA
formed during unwinding of the parental duplex and as a result of blockage of replicative
DNA synthesis [Wold et al., 1997; Raderschall et al., 1999]. Interestingly, previous
studies have shown WRN and RPA co-localization in nuclear foci in response to
treatment with HU, indicating that these proteins function at the same site and suggesting
that they might interact within a complex at blocked replication forks [Constantinou et
al., 2000]. If so, it should be possible to detect interactions between WRN and RPA
within cells in response to DNA damaging treatments known to block replication. To
explore this possibility, we used co-immunoprecipitation methods that we developed
earlier (see chapter II) to identify proteins that are putative members within a complex. If
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WRN and RPA are part of the same complex, by targeting one of them with an antibody
it is possible to pull the intact protein complex out of the cell (and thereby identify the
other one as a member of the same complex). For these experiments, we use human
fibroblasts treated either for 10 h with or without HU, an agent that blocks DNA
replication by exhausting deoxynucleotide pools within cells, or for 4 h with or without
the alkylating agent MMS, that produces methylated bases that block DNA replication.
Both agents alter the subnuclear localization profile of WRN [Wyatt et al., 2006,
Karmakar et al., 2005]. Since WRN and RPA possess DNA binding activities [Orren et
al., 1999; Brosh et al., 2002; Bochkareva et al., 2002], it was possible that association
might occur indirectly through DNA. Therefore, we used two strategies to minimize the
possibility that protein interactions were mediated through DNA bridging: 1) DNase I
was employed during lysis and immunoprecipitation to thoroughly digest DNA from
protein samples, and 2) ethidium bromide was included during washing of the
immunoprecipitate to intercalate DNA strands and thereby destabilize potential proteinDNA interactions. A schematic representation of the protocol used is shown in Figure
4.1. Briefly, we used an antibody against the RPA32 subunit for immunoprecipitation and
antibodies

against

WRN

and

RPA32

for

immunodetection.

Analysis

of

immunoprecipitates by immunoblotting with RPA antibody demonstrated that the level of
RPA was equal in the immunoprecipitated fraction in HU- and MMS-treated and
untreated cells (Figure 4.2A, lower panel), indicating that we immunoprecipitated
equivalent amounts of RPA in each sample and that RPA expression or abundance not
changed by HU or MMS treatment. Even in untreated cells, we were able to detect
endogenous WRN co-immunoprecipitated along with RPA, demonstrating an association
between WRN and RPA even in the absence of exogenous damage (Figure 4.2, upper
panel, lanes 2 and 5). Interestingly, the amount of WRN precipitated with RPA is
substantially higher in MMS-treated cells (Figure 4.2A, upper panel, lanes 2 vs. 3).
Similar results were obtained with HU-treated cells (Figure 4.2A, lanes 5 vs. 6).
Quantitation of data from multiple independent experiments indicates that MMS results
in a 4.4 fold increase and HU results in a 2.0 fold increase in the levels of WRN
interacting with RPA (Figure 4.2B). Thus, WRN and RPA are co-immunoprecipitated
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Figure 4.1 Schematic representation of the procedure used
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Figure 4.2 DNA damage enhances the co-immunoprecipitation of WRN with RPA.
A) Cells incubated with or without MMS (1 mM) for 4 h or HU (2 mM) for 10 h were
prepared for immunoprecipitation using anti-RPA32 subunit monoclonal antibody as
described in Methods. Aliquots (40 μl) of the resuspended immunoprecipitated fractions
from untreated (lanes 2 and 5), MMS-treated (lane 3), and HU-treated (lane 6) lysates
were analyzed by SDS-PAGE (6%) and Western blotting using anti-WRN antibody and
chemiluminescent detection (upper panel). In parallel, aliquots (2.5 μl) of these same
immunoprecipitated fractions were analyzed by SDS-PAGE (12%) and Western blotting
using anti-RPA32 antibody (lower panel). Purified WRN and RPA were loaded as
protein markers (Mkr, lanes 1 and 4). B) Quantitative bar graph for WRN-RPA
interaction under conditions described above (mean and S.D. for three independent
experiments).
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from cell lysates, suggesting that they are associated within the same complex in vivo.
More importantly, this interaction is significantly increased following treatments known
to block DNA replication.

WRN and RPA association occurs via a direct interaction. The experiments above
show an association between WRN and RPA in vivo. However, proteins might interact
directly or indirectly, via one or more linked proteins. Thus, we wanted to analyze
whether WRN and RPA association occurs via a direct interaction. Thus, we tested
whether purified WRN and RPA could bind to each other by a Far Western dot blotting
method that is used to analyze specific protein-protein interactions. Briefly, several
concentrations of one protein were immobilized on nitrocellulose membranes. The
membranes were blocked with 5% milk solution to saturate any non-specific binding sites
and then incubated in buffer containing the other protein of interest. As a control for nonspecific binding, the same amounts of BSA were separately spotted onto the same
membrane. Then, membranes were subjected to immunodetection by incubation with
anti-WRN or anti-RPA32 antibodies to assess binding of the proteins. Figure 4.3A shows
that when RPA was spotted onto the membrane, WRN binds to RPA in a manner
dependent on the RPA concentration. Similar results were obtained when WRN was
spotted onto the membrane. Specifically, RPA bound exclusively to WRN in amounts
dependent on WRN concentration (Figure 4.3B). No non-specific binding of WRN or
RPA to BSA was observed. Additionally, we tested the stability of WRN-RPA
interaction. To this end, we analyzed the effect of increasing concentrations of NaCl on
the WRN-RPA interaction. Interestingly, similar amounts of RPA bound to WRN at
NaCl concentrations of 25 mM and (more physiologically relevant) 100 mM (Figure
4.3B). Therefore, we can conclude that WRN and RPA association occurs via a direct,
salt tolerant interaction.
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Figure 4.3 RPA and WRN directly interact with each other. For Far Western analysis,
purified RPA (A), WRN-E84A (B), and BSA (both, as a control for non-specific binding)
were immobilized on nitrocellulose membranes at the concentrations indicated above
each panel. After blocking, membranes were then incubated in buffer containing 25 or
100 mM NaCl as indicated at left and either (A) WRN-E84A (400 ng = 2.4 pmol) or (B)
RPA (360 ng = 3 pmol). As described in Methods, immunodetection and autoradiography
were used to assess binding of the protein in solution to the immobilized protein on the
membrane. The amounts of RPA bound to immobilize WRN (indicated below
corresponding spots in B) were determined by comparison to an RPA standard (50 fmol)
spotted on each membrane.
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DISCUSSION

To safeguard genome stability, cells rely on an accurate response to replication stress.
The observed enhanced genomic instability and diminished replicative lifespan of WS
cells highlight the importance of WRN in DNA metabolism and maintenance of genomic
stability. Several lines of evidence support the view that WRN might play a critical role
in the response to replication stress, specifically in the response to stalled replication
forks. In agreement with this notion, WRN co-localizes with replication factors, including
RPA, in response to treatment with DNA damaging agents and the replication inhibitor
HU [Constantinou et al., 2000]. Therefore, it should be possible to detect interactions
between WRN and RPA in vivo, particularly in response to replication blocking agents.

In this study we clearly demonstrate, by co-immunoprecipitation experiments, an
association between WRN and RPA in vivo. Importantly, we also demonstrated that
WRN-RPA interaction significantly increased after MMS and HU, agents known to block
replication. This is the first time that co-immunoprecipitation of endogenous WRN and
RPA has been demonstrated, as well as its enhancement by genotoxins. These results
indicate that, in response to replication blockage, WRN and RPA associate in the same
protein complex in vivo. This binding appeared not to be mediated by DNA, because the
interaction persists in the presence of ethidium bromide and DNase I and is substantially
increased after MMS or HU treatment. Our results are consistent with studies
demonstrating that WRN and RPA orthologs in C.elegans cooperate at blocked
replication forks after HU, and that WRN is required for the efficient formation of RPA
foci in response to DNA replication inhibition [Yan et al., 1998, Lee et al., 2010].

Although our results support the notion that WRN and RPA play a part in the same
protein complex, they do not prove a direct physical association between them. Hence,
we tested whether recombinant WRN and purified RPA could bind to each other by Far
Western dot blotting analysis. The results demonstrated that WRN bound RPA directly.
Notably, the interaction is stable even at physiologically relevant salt concentrations.
Taken together, our data strongly suggest that co-immunoprecipitation of WRN and RPA
81

is mediated by a direct interaction between them. Importantly, our results are consistent
with previous reports showing a direct interaction between purified WRN and RPA.
According to these studies, the interaction between WRN and RPA occurs thru the Nterminal region of WRN (aa239-499) and the RPA70 subunit (aa100-300) [Brosh et al.,
1999; Doherty et al., 2005; Shen et al., 2003].

It is believed that during DNA replication different DNA lesions can pose a serious
threat to genome integrity by interfering with fork stability. Those lesions will influence
how the blocked replication fork structure will be processed to restart DNA replication.
Proposed models for resolution of replication blockage suggest that one of the first steps
involves fork regression to generate a Holliday junction or “chicken foot” intermediate
[Haber et al., 1999; Cox et al., 2002]. The unwinding and annealing activities of WRN
suggest that WRN would be suitable to perform fork regression. In response to HU
treatments, WRN is subject to translocation from nucleolus to nuclear foci (considered as
sites of blocked replication) where it co-localizes with RPA [Constantinou et al., 2000].
This evidence suggests that WRN and RPA might interact at blocked replication forks,
facilitating WRN function in proper resolution of replication blockage. Consistent with
this notion, several studies have shown that: 1) RPA enhances WRN unwinding strength
[Shen et al., 1998a; Brosh et al., 1999], 2) WRN has a preferential action on complex
DNA structures, including replication forks [Huang et al., 2000; Brosh et al., 2001;
Opresko et al., 2004; Orren et al., 2002], 3) WRN specifically regresses replication forks
[Machwe et al., 2006], and 4) WRN displaces RPA from a replication fork substrate
independently of its catalytic activity and subsequently remodels/regresses this
replication fork [Machwe et al., 2011]. Based on these findings, we propose a possible
scenario as to how WRN and RPA might function cooperatively to resolution of stalled
replication forks. Upon replication blockage, RPA binds to resulting single-stranded
DNA gaps and helps to recruit WRN to blocked forks via a direct interaction between
these two proteins. WRN regresses the fork and displaces RPA in the process.
Subsequently, the regressed fork is subsequently processed and replication is restarted.
Since we previously demonstrated that WRN is modified, specifically acetylated, in
response to DNA damage and/or replication blockage, and WRN acetylation [Blander et
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al., 2002] and phosphorylation [Pichierri et al., 2003] correlates with its relocalization
from nucleolus to nuclear foci where it colocalizes with RPA, it is possible that a
modified form of WRN might mediate or enhance the WRN-RPA interaction.

Copyright © Enerlyn Meliza Lozada Santiago 2011
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CHAPTER V

CONCLUSIONS AND FUTURE DIRECTIONS
The primary objective of our studies was to further clarify the role of WRN in
response to agents that damage DNA and/or block replication, with a particular emphasis
on the relationship of acetylation of WRN with its function in DNA metabolism. In 2002,
Blander et al. made the observation that WRN can be acetylated in vivo by the
acetyltransferase p300 [Blander et al., 2002], and that this modification correlates with its
translocation from the nucleolus into nucleoplasmic foci. These findings suggested that
WRN acetylation could play an important role in regulation of WRN function, a concept
that has been reinforced by the experiments presented here. It is also noteworthy that
WRN is also subject to phosphorylation and sumoylation.
In Chapter II, we addressed the dynamics of endogenous WRN acetylation and its
relationship to DNA damage. To this end, we measured the levels of WRN acetylation
after DNA damaging agents and replication blocking agents. The results of those
experiments revealed that WRN is detectably acetylated under normal conditions.
However, certain DNA damaging agents (MMS, MMC, cisplatin, but not UV) and
inhibitors of DNA replication such as HU significantly increase WRN acetylation. Our
results are consistent with a study showing WRN acetylation after treatments with DNA
damaging agents, such as MMC [Karmakar et al., 2005]. Importantly, our results using
inhibitors of standard repair pathways to suppress DNA damage removal extend those
observations in two ways. First, our results confirm that WRN acetylation itself is, at
least in part, related directly to DNA damage and not some non-specific effect of the
treatment on some other aspect of cellular metabolism or physiology. Second, since we
demonstrated that inhibition of repair of certain lesions induced further amplification of
WRN acetylation, our results revealed that it is not the induction of damage but its
persistence that optimally enhances WRN acetylation. Thus, our results suggest that
WRN acetylation is a downstream effect of certain types of DNA lesions on DNA
metabolism. Since all of the agents that enhance WRN acetylation in our studies are
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known to either directly cause or produce lesions that result in blockage of replication,
the results of our experiments strongly suggest that WRN might be acetylated in response
to stalled or blocked replication. In agreement with this notion, we showed that increases
in the levels of acetylated WRN correlate with inhibition of DNA synthesis and an
increase in the percentage of S-phase cells.
Since the acetylation state of proteins in humans is regulated by acetylases and
deacetylases, we used deacetylase inhibitors to investigate the role of deacetylases in
regulation of WRN acetylation. The results of our experiments revealed that WRN is
actively deacetylated in vivo and that, even in untreated cells, WRN acetylation state is
determined by an equilibrium between acetylation and deacetylation. These results are in
agreement with studies showing WRN regulation in response to deacetylase inhibitors,
since it has been shown that WRN translocates from the nucleolus to nucleoplasmic foci
in response to TSA treatment [Blander et al., 2002]. Since our previous studies
demonstrated enhancement of WRN acetylation after DNA damaging and replication
blocking treatments, a possible explanation for our results is that blockage of replication
by DNA damage or other circumstances shifts the equilibrium towards acetylation.
Previous studies have shown that WRN function is influenced by the sirtuin family of
deacetylase enzymes, including SIRT1 [Li et al., 2008 and 2010; Law et al., 2009; Kahyo
et al., 2008; Michishita et al., 2008]. Notably, we demonstrated for the first time that
members of the classical HDAC family of deacetylase enzymes appear to play a role in
WRN deacetylation. In fact, our results suggest that HDACs may play the predominant
role, since inhibition of HDACs (using TSA) resulted in higher levels of WRN
acetylation when compared to inhibition of sirtuins (using nicotinamide).
To investigate the effect of WRN acetylation on its biochemical function,
unmodified, acetylated, and deacetylated WRN were compared as to their helicase,
exonuclease and fork regression activities on different DNA structures. Our data
demonstrated that acetylated WRN has dramatically less helicase and exonuclease
activities than unmodified WRN on simple DNA substrates. Conversely, deacetylation of
WRN restored the helicase and exonuclease activities to near normal levels. These
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experiments initially suggested that WRN acetylation might regulate WRN enzymatic
function in a negative manner. However, since WRN has preference for complex DNA
structures, such as DNA replication and recombination intermediates, we explored WRN
action on those kinds of substrates. When a more rigorous examination was performed on
complex DNA substrates (such as replication forks), the effect of acetylation on WRN
fork regression activity and exonuclease activity on those substrates was substantially
less pronounced. Collectively, our results suggest that WRN acetylation regulates WRN
specificity by reducing its preference for non-physiological DNA substrates. This
supports the idea that WRN acetylation is likely to be critical for its contribution to
genomic integrity surveillance. Since our data indicate that WRN acetylation might
increase WRN specificity by reducing preference for non-physiological substrates,
further DNA binding assays are required to explore if the binding of acetylated WRN to
the different DNA structures correlates with the results obtained in our helicase,
exonuclease, and fork regression assays. Based on our results, we speculate that WRN
acetylation (as well as other post-translational modifications) may serve as a rapid way to
respond to cellular stress and restart replication. By this reasoning, acetylation may be
involved in reducing WRN affinity for nucleolar DNA while maintaining affinity for
replicative DNA structures associated with replication foci. Consistent with this notion,
previous studies have shown that WRN acetylation correlates with its translocation to
nuclear foci in response to DNA damage and replication blockers [Blander et al., 2002;
Karmakar et al., 2005]. WRN also assists the pairing of complementary DNA strands.
Thus, unmodified and acetylated WRN should be compared in future experiments to
investigate the effect of acetylation on WRN annealing activity.
In our experiments, we measured overall acetylation of WRN. Interestingly, our
results suggest that the status of WRN acetylation might be regulated by different
conditions, such as DNA damage and disruption of the equilibrium between acetylases
and deacetylases. However, it is unclear if independent acetylation events occur on
different lysine sites upon different conditions and/or DNA damaging treatments. A
recent study identified putative acetylated lysine residues (K366, K887, K1117, K1127,
K1389, and K1413) in WRN using ectopically expressed WRN and the acetylases p300
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and CBP [Li et al., 2010]. However, it would be informative and more physiologically
relevant to identify WRN acetylation sites on endogenous WRN, using mass
spectrometry analysis. Such an analysis would explore if, indeed, all or a subset of these
residues are the actual sites subject to acetylation in the native environment of cells--i.e,
with endogenous levels of WRN and the relevant acetylases. The same technique can be
used after treatment of cells with the different DNA damaging agents, or the deacetylase
inhibitors, to explore differential patterns of acetylation between the different treatments.
The immunoprecipitation protocols developed for these studies should be useful for
isolating modified and unmodified WRN for these types of experiments. If the different
treatments target different residues, those studies should provide valuable insight in
regard to functional differences between the various acetylation events and if there is any
hierarchy in the acetylation of different lysine residues.

In addition, site-directed

mutagenesis can be used to mutate the putatively acetylated lysines to investigate which
modifications affect WRN biochemical activities. Specifically, those mutants can be used
in DNA binding assays as well as helicase and exonuclease assays, to determine if
specific mutations (or combinations of mutations) affect the interaction of lysine residues
with the negatively charged backbone of DNA. To directly determine the effect of WRN
acetylation on its cellular function, WRN cDNAs containing lysine to arginine (a
conservative basic substitution that cannot be acetylated) point mutations at putative
acetylation sites can be constructed and transfected into WRN-deficient cells to compare
the ability of wild-type and acetylation-deficient WRN to complement the
hypersensitivity of WS cells to HU and DNA damaging agents as well as other
phenotypes of WRN-deficient cells.
The data described herein suggest that WRN is regulated in response to DNA damage
and replication blocking agents. To confirm this relationship and investigate it further, we
analyzed if DNA damage regulates the nature of WRN’s potential interactions in
response to treatments that block replication. Specifically, we investigated the potential
interaction between WRN and the single-stranded DNA binding protein complex, RPA,
and whether it is altered in response to treatment with HU or MMS. Our experiments
revealed that WRN and RPA associate with each other even under normal physiological
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conditions in vivo. Interestingly, treatments that block replication fork progression induce
an increased association between these two factors. As we also demonstrated that purified
WRN and RPA bind to one another, this association in vivo is also likely to be direct. The
results of our experiments confirm previous findings showing interaction between
purified WRN and RPA [Brosh et al., 1999; Doherty et al., 2005; Shen et al., 2003].
Importantly, our results substantially extended those findings by showing endogenous
WRN-RPA interaction in the native environment of cells, as well as its enhancement by
treatments that block replication. It is known that RPA is hyperphosphorylated in
response to treatment with DNA damaging agents and replication blocking agents
[Oakley et al., 2001; Shao et al., 1999; Anantha et al., 2009]. Thus, future coimmunoprecipitation experiments could be performed to analyze if WRN specifically or
preferentially interacts with the hyperphosphorylated form of RPA. On the other hand,
the addition of acetyl groups to lysine residues on WRN after DNA damage may create a
new surface for protein association(s). Thus, it will be interesting to explore as well
whether and how acetylated forms of WRN interact with RPA and if this is influenced by
treatment with agents that block replication.
In summary, through this study, we provided some interesting and revealing results
that support the likely importance of WRN regulation in response to DNA damage and
blockage of replication. Collectively, our results suggest that WRN acetylation is a
downstream effect of DNA damage on DNA metabolism which influences WRN
function, including altering its specificity by reducing preference for non-physiological
substrates. Thus, the results of the studies presented in this work have identified unique
mechanisms by which WRN is regulated in response to DNA damage. Importantly, our
results are consistent with evidence pointing to a role for WRN in response to blocked
replication, including its recruitment to sites of ongoing and/or blocked replication upon
DNA damage and its ability to regress model replication forks. Based on our findings and
the existing evidence, we propose a possible scenario for how loss of WRN function
(possibly caused by problems with regulation of WRN acetylation) in DNA metabolism
might result in the cancer and premature aging phenotypes typically associated with WS
(Figure 5.1). An inability to properly resolve blocked replication forks, due to loss or
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Figure 5.1 Schematic representation of the downstream effects caused by loss of
WRN function. Loss of WRN function (possibly caused by problems with regulation of
WRN acetylation) in DNA metabolism might result in the inability of cells to properly
resolve replication blockage and thereby increase genomic instability. These DNA
metabolic problems might cause chromosomal abnormalities and activate checkpoints
that, in turn, might trigger cell death and cellular senescence; processes that result in the
accelerated development of age-related phenotypes and elevated cancer frequency
associated with WS.
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dysfunction of WRN, may further delay or cause collapse of DNA replication, triggering
overall genomic instability and activation of checkpoint pathways that, in turn, might
trigger cellular senescence and cell death; two mechanisms that are thought to drive
certain aging processes. Genomic instability may also contribute to chromosomal
aberrations, potentially driving carcinogenesis. This model would be consistent with the
increased cancer incidence and aging phenotypes in WS. However, further research is
needed to determine if, indeed, acetylation of WRN is essential to minimize large-scale
chromosomal aberrations and prevent the development of age-related phenotypes. To
investigate the role of acetylated WRN in the pathogenesis of aging, WRN cDNAs
containing lysine mutations at putative acetylation sites can be constructed and
transfected into WRN-deficient cells to compare the ability of wild-type and acetylationdeficient WRN to complement the premature cellular senescence of WS cells as well as
other age-related phenotypes of WRN-deficient cells. The same strategy can be used to
measure genomic instability, using techniques such as the micronucleus assay, to
determine whether and to what extent loss of WRN acetylation might contribute to the
development of cancer. Alternatively, loss of function or dysregulation of acetylases and
deacetylases that disrupt the equilibrium in the process of WRN acetylation might also be
used as a possible strategy. Thus, creating a cell culture model in which the balance
between acetylation and deacetylation is altered by knocking down and/or overexpressing
specific deacetylases and acetylases involved in the WRN acetylation process, such as
p300, may help to determine the importance of acetylated WRN in processes such as
cellular senescence and carcinogenesis. To examine whether WRN acetylation was
required for suppression of age-related and cancer phenotypes at the physiological level,
specialized transgenic mouse models would have to be developed in which mutated
WRN genes, incapable of acetylation as described above but otherwise catalytically
unaffected, are re-introduced into mice lacking functional WRN and telomerase; notably,
telomerase deficiency is necessary to reveal WRN-related cancer and aging phenotypes
in mice (Chang et al. 2004). Although many questions regarding WRN acetylation and its
function remain to be answered, our findings provided mechanistic insights into the role
of WRN in DNA metabolism. Importantly, our work revealed that WRN acetylation is a
fascinating area of research to keep our attention well into the future.
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APPENDIX

LIST OF ABBREVIATIONS
ATM: Ataxia telangiectasia mutated protein kinase
ATP: Adenosine triphosphate
ATR: ATM and Rad3-related protein kinase
BER: Base Excision Repair
BLM: Bloom Syndrome Protein
BN: Binucleated
bp: Base pairs
BrdU: Bromodeoxyuridine
CBP: CREB-binding protein
cDNA: complementary DNA
DNA: Deoxyribonucleic acid
DNA-PK: DNA-dependent protein kinase
EDTA: Ethylenediaminetetraacetic acid
FEN-1: Flap Endonuclease I
fmol: femtomol
HAT: Histone acetyltransferase
HDACs: Histone Deacetylases
HEK293: Human Embryonic Kidney 293 cells
HRDC: Helicase and RNase D C-terminal
HU: Hydroxyurea
IP: Immunoprecipitation
MGMT: Methylguanine methyltransferase
MMC: Mitomycin C
MMS: Methylmethanesulfonate
MN: Micronucleus
MRK: Marker
NAD+: Nicotinamide adenine dinucleotide
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N.D.: Non-detectable
NER: Nucleotide Excision Repair
NER+: Nucleotide Excision Repair Proficient
NER-: Nucleotide Excision Repair Deficient
NIC: Nicotinamide
O6-BG: O6-benzylguanine
PARP: Poly (ADP-ribose) polymerase
PCNA: Proliferating Cell Nuclear Antigen
pmol: picomol
PMSF: Phenylmethylsulfonylfluoride
PVDF: Polyvinylidene Fluoride
RPA: Replication Protein A
RECQ: RecQ helicase
RQC: RecQ-conserved
S.D.: Standard Deviation
SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SIRT1: Sirtuin 1
ssDNA: Single-stranded DNA
SUMO: Small Ubiquitin-like Modifier
TOPO I: Topoisomerase I
TSA: Trichostatin A
UV: Ultraviolet
WB: Western Blot
WRN: Werner Protein
WS: Werner Syndrome
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